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Abstract 
Mucins play an important protective and lubricative function in the oral 
cavity. They protect hard and soft tissues from desiccation, mechanical abrasion 
and exogenous insults. These functions are related to the structural properties of 
the mucin glycoproteins. The major high molecular weight mucin in salivary 
secretions has been identified as the MUC5B gene product, which is a large 
secreted gel-forming mucin. The major low molecular weight mucin in salivary 
secretions has been identified as the MUC7 gene product, which is a small 
secreted mucin. Another class of mucin molecules, the membrane-bound 
mucins, is structurally and functionally distinct from MUC5B and MUC7. Two of 
the membrane-bound mucins, MUC1 and MUC4, are expressed in all major 
human salivary glands as well as in buccal epithelial cells. The secreted forms of 
these mucins are also found at low levels in saliva. The aims of this study were: 
1) to confirm the expression of membrane-bound mucin MUC 1 in oral epithelial 
cells, 2) to determine whether the membrane-bound mucin MUC 1 can form 
complexes with the secreted mucin MUC5B and to localize the MUC1 binding 
sites on the MUC5B polypeptide backbone and 3) to identify other proteins from 
a salivary protein pool which can form heterotypic complexes with MUC 1. 
In the first part of this study, epithelial cells from six healthy volunteers 
were removed from buccal surfaces using cell scrapers. Reverse transcriptase-
polymerase chain reaction and Western blotting demonstrated the presence of 
MUC 1 mRNA transcripts and protein in buccal epithelial cells. 
V 
lmmunohistochemistry also detected MUC1 protein expression in 
epithelial cells on normal buccal specimens and increased expression on gingival 
tissues with inflammation. The results confirmed that MUC1 was expressed by 
oral epithelial cells. 
In the second part of this study, the N-terminal domain I of MUC1 (residue 
1-107) was expressed as a glutathione S-transferase fusion protein (GST-M 1) in 
Escherichra coli. Affinity purified MUC58 was isolated from 
submandibular/sublingual secretion. Interactions between GST-M1 and MUC58 
were evaluated in GST pull-down assays and examined by Far-Western blotting. 
Interacting domains were then identified using the yeast two hybrid system with 
pair-wise transformations containing a MUC1 bait vector and one of a series of 
target vectors expressing 5 different MUC58 domains. Yeast two hybrid mapping 
showed that MUC1/MUC58 interactions probably occur through the C-terminal 
CK domain of MUC58. 
In the third part of this study, the N-terminal domain I (107 residues) and 
C-terminal domain II (191 residues) of MUC1 were cloned into the yeast bait 
vector pGBKT7 that contains the GAL4 DNA binding domain. Each of the 
constructs was used as ,bait to identify novel protein-protein interactions in a 
salivary protein library expressed in the yeast prey vector pGADT7 fused with the 
GAL4 activation domain. Two hybrid screens identified MUC7, basic praline rich 
proteins and parotid secretory protein as salivary secretory proteins which 
interacted with MUC1. In addition, the transmembrane proteins M83, ICAM-3, 
Vl 
actin binding protein 280 and epithelial cell receptor protein tyrosine kinase were 
also identified as MUC1 complex partners . Interactions between MUC1 and 
some of these proteins were confirmed by yeast co-transformation and Far 
Western Blotting. 
This study demonstrated the expression of membrane bound mucin 
MUC1 in oral epithelial cells. MUC1 may form heterotypic complexes with 
secreted mucins and other salivary proteins to form the protective scaffold on 
oral epithelial surfaces. In addition, interactions between MUC1 and other 
transmembrane proteins may play an important role in cell adhesion and signal 
transduction. 
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Introduction 
I. Mucins 
Mucins are a class of multimeric or monomeric glycoproteins. They are 
made up of approximately 15% to 20% protein and 80% carbohydrate (Strous 
and Dekker, 1992; Gendler and Spicer, 1995). As the principal protein 
components of the mucous layer on the epithelial surface, mucins form a viscous 
barrier protecting the underlying epithelium (Nieuw Amerongen et al., 1998). In 
general, multimeric mucins are secreted while monomeric mucins remain 
membrane associated. 
In general, multimeric mucin molecules have an oligomeric structure 
consisting of monomeric glycoprotein subunits covalently linked by disulfide 
bonds. The basic subunit of most mucins is a single polypeptide chain that 
consists of three regions: a heavily glycosylated central tandem repeat (TR) 
region and two flanking (N- and C- terminal) regions (Moniaux et al., 2001 ). 
Serine and threonine are the most abundant amino acids in the TR and serve as 
the attachment site for O-linked carbohydrates. The tandem repeated sequences 
range from 8 to 169 amino acids in length and may be repeated hundreds of 
times with little variation. O-linked glycosylation predominates over N-linked 
glycosylation and the length of the O-glycans ranges from 1 to 20 sugar residues 
in most cases (Devine and McKenzie, 1992). The O-glycans in mucin TRs 
present multivalent carbohydrate antigenic or functional determinants for 
antibody recognition, mammalian cell adhesion and binding of microorganisms. 
There is no known consensus amino acid sequence signal for O-glycosylation 
although the flanking sequences around serine and threonine may have some 
effect (O'Connell et al., 1991; Pisano et al., 1993; Nehrke et al., 1996). Unlike the 
0- link, the consensus sequence for the N-linked glycans is Asn-X-Ser/Thr, in 
which X cannot be praline or aspartic acid. The function of the N-glycans in 
mucins is not clear. They may play a role in the packaging of mucin into 
secretary vesicles and subsequent secretion from cells (Perez-Vilar et al., 1998). 
The N- and C- terminal regions are non- or sparsely glycosylated with both O-
and N- linked sugars. In many mucins, these regions are cysteine-rich and 
appear to form disulfide bonds to stabilize mucin multimers. The N- and C-
terminal regions may also have some other biological properties in mucin-mucin 
interactions. 
By now, at least 19 distinct human mucin genes have been identified and 
numbered in chronological order of their description. They are MUC1, MUC2, 
MUC3, MUC4, MUC5AC, MUC5B, MUC6, MUC7, MUC8, MUC9, MUC11, 
MUC12, MUC13, MUC15, MUC16, MUC17, MUC18, MUC19, and MUC20. 
These mucins are divided into three major classes: the large gel-forming mucins ; 
the large membrane-associated mucins, and the small soluble mucins. Some 
MUC genes (MUC8, MUC9, MUC11) do not fit well into any class. 
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1.1. Large gel-forming mucins 
The large gel-forming mucins are what are commonly thought of as 
"mucins". They exist as the secreted form of high molecular weight multimers. 
Currently, five gel-forming mucin genes have been identified: MUC2, MUC5AC, 
MUC5B, MUC6, and MUC19. All of these genes have five major cysteine-rich 
domains (four von Willebrand factor C or D domains and one Cystine-knot [CK] 
domain) as their distinctive features , in contrast to other non-gel-forming types of 
mucins. The CK domain is believed to be involved in the initial mucin dimer 
formation and the positions of cysteine residues in CK domains are conserved in 
different gel-forming mucins and even across species (Chen et al., 2004) . Gel-
forming mucins are major contributors to the viscoelastic properties of mucus 
secretion. They provide a protective barrier between the environment and 
underlying epithelium and participate in the innate host defense system (Tabak, 
1995). 
1.2. Membrane-associated mucins 
The membrane-associated mucins are structurally and functionally distinct 
from the gel-forming mucins. These proteins do not form multimers and can exist 
as both secreted and membrane-bound forms, with the latter anchored to 
epithelial cell membranes through a short membrane-spanning domain (Offner 
and Troxler, 2000). MUC1, MUC3, MUC4, MUC12, MUC13, MUC15, MUC16, 
3 
MUC17, MUC18, and MUC20 are in this group. The membrane-bound mucins 
may function as receptors in cell signal transduction because they have three 
regions: extracellular, transmembrane and intracellular, and their structures 
therefore resemble those of many known receptors. Their functional properties 
are likely to be different from those of the gel-forming mucins and more studies 
are needed to aid in the understanding of their importance. 
1.3. Small secreted mucin 
MUC7 is the only known low molecular weight secreted mucin (Bobek et 
al., 1993). Compared to other high molecular weight secreted mucins, it lacks 
cysteine-rich domains and is thought to be secreted as a soluble monomer, not a 
disulfide bond linked multimer as are other secreted mucins (Lagow et al., 1999). 
MUC7 does not contain either D domains or a CK motif in its N- or C- terminal 
regions . Functionally, MUC7 is involved in the non-immune host defense system 
as it has been shown to bind a number of strains of oral microbes. The 
antimicrobial activity of MUC7 will be discussed further in Section I1.1.b. 
II. Mucins in oral cavity 
Mucins are the major organic constituents of mucus that coats all epithelial 
surfaces. Compelling evidence suggests that these glycoproteins play an integral 
role in non-immune protection in the oral cavity. In the oral cavity, mucins are 
secreted by both major and minor salivary glands and by oral epithelial cells 
4 
(Levine et al., 1987; Offner and Troxler, 2000; Liu et al., 2002a). They constitute 
a major factor in the defense of teeth against abrasion, erosion and caries (AI-
Hashimi and Levine, 1989; Slomiany et al., 1986; Slomiany et al., 1989; 
Banderas-Tarabay et al., 2002). They are also important to protect oral mucosa 
and soft gingival tissue from mechanical, chemical, and microbial insults 
(Mandel, 1987). Specific functions of the oral mucins include: 1) protection 
against desiccation and environmental insult, 2) lubrication, 3) antimicrobial 
effects against potential pathogens and 4) cell-associated adhesion and signal 
transduction (Tabak et al., 1982; Kam et al., 1998; Chan et al., 1999; Hayashi et 
al., 2001; Li et al., 2003a). 
Mucins in the oral cavity exist in two distinct forms: secreted mucins and 
membrane-bound mucins. The secreted mucins are important constituents of 
saliva and are known as "salivary mucins". The membrane-bound mucins are 
attached to epithelial cell surfaces, but can also exist as secreted forms with the 
extracellular portion being released from the cell membrane. 
11.1. Salivary mucins 
As noted above, salivary mucins play an important role in the maintenance 
of the viscqelastic properties of saliva. They facilitate speech, mastication and 
swallowing, participate in the formation of the protective oral mucosal mucus coat 
and tooth enamel pellicle (Slomiany et al., 1986; Slomiany et al., 1989), promote 
bacterial aggregation and clearance from the oral cavity (Tabak, 1990) and 
5 
modulate and regulate the epithelial cell process (Slomiany et al., 1993a; 
Slomiany et al., 1993b; Slomiany et al., 1993c). 
It is generally accepted that mucins in saliva occur as two biochemical 
entities in different molecular weight forms: high molecular weight salivary mucin 
MG1 and low molecular weight salivary mucin MG2. 
11.1.a. MG1 
High molecular weight salivary mucin (MG1) accounts for about 30% of 
human salivary mucins (Slomiany et al., 1996). The molecular weight of MG1 is 
around 20-40 million Daltons and compositional analyses showed that it contains 
15% protein, 78% carbohydrate and 7% sulfate. Serine, threonine and praline 
constitute 35% of the polypeptide chain (Loomis et al., 1987). The carbohydrate 
units of MG1 are primarily O-linked glycans with 4-16 sugar residues (Levine et 
al., 1987). The 'naked' unglycosylated polypeptide moiety of MG1 is involved in 
its binding to Hemophilus parainfluenzae (Veerman et al., 1995). The sulfated 
carbohydrates on MG1 can bind to Helicobacter pylori (Namavar et al., 1998). 
MG1 can also bind with Actinobacillus actinomycetemcomitans (Groen ink et al., 
1998) and interact with the surface of E. coli (Moshier et al., 1996). Recent 
studies have shown that MG1 contains both MUC58 and MUC4 gene products 
(Nielsen et al., 1997; Troxler et al., 1997; Liu et al., 1998; Thornton et al., 1999) 
and it is likely that MG1 also contains the recently described mucin, MUC19, as 
well (Chen et al., 2004 ). 
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MUC58 is the major component of MG1 and this gene product is 
expressed in mucous cells in the sublingual, submandibular, palatine and labial 
glands in the oral cavity (Troxler et al., 1995; Nielsen et al., 1997; Wickstrom et 
al., 1998). The complete nucleotide sequence of MUC58 has been determined 
by several groups. 
The deduced sequence of the N-terminal region of MUC58 (Figure 1) 
contains 1321 amino acids organized into a short, putative signal peptide with 25 
residues, a 50 residue mucin like domain enriched with threonine, serine and 
praline, three von Willebrand factor-like O domains (01, 02 and 03) enriched 
with cysteine and containing 11 potential N-glycosylation sites, and a 71 residue 
cysteine-rich domain which connects to the TR (Offner et al., 1998). Compared to 
other gel-forming mucins, the N-terminal sequence of MUC58 displays 46% and 
59% similaritiy to the N-terminal regions of MUC2 (Gum et al., 1994) and 
MUC5AC (Li et al., 1998a), respectively. There are a total of 124 cysteine 
residues in the N-terminal region of MUC58 and 105 are conserved in all three 
mucins, suggesting that this region contains determinants necessary for the 
assembly or functional properties of the gel-forming mucins. MUC58 also 
contains some specific structural motifs in the 01, 02 and 03 domains that were 
not previously recognized in other mucins (Offner et al., 1998). These include a 
consensus motif for C-type lectin domain protein as well as a motif common to 
selectin complement binding repeats in its 03 domain; a block of LOL receptor 
repeats and an EGF-like domain in all of the three O domains. These domains 
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may be important in mucin-ligand interactions and the formation of heterotypic 
complexes with other salivary proteins. 
Following the N-terminal region is the central tandem repeat (TR) region of 
MUC58. The TR has 10,713 base pairs and encodes 3570 amino acids 
(Desseyn et al., 1997). Nineteen subdomains have been identified. Seven of 
these subdomains, Cys 1 to Cys 7, contain 108 amino acids with 10 cysteine 
residues and one conserved O-glycosylation site with no potential N-
glycosylation sites . These subdomains show a very similar organization to 
corresponding domains in MUC2 (Toribara et al., 1991) and MUC5AC (Guyonnet 
Duperat et al., 1995). Between Cys1-Cys2 and Cys2-Cys3, there are 
subdomains R01 and R02. These domains are enriched with threonine, serine, 
praline and alanine but contain no repeats. Downstream of the regions coding for 
the cysteine-rich subdomains Cys3 to Cys7, five subdomains (RI to RV) 
composed of various numbers of 87-bp imperfect TRs are encountered . These 
subdomains comprise four super-repeats (RI-RIV) and a 29-residue subdomain 
(RV). Each super-repeat contains 528 residues including a subdomain 
composed of 11 irregular 29 amino acid repeats, a unique conserved 111 residue 
subdomain with no typical repeat but rich in threonine, serine and alanine, and a 
cysteine-rich subdomain. This latter subdomain has high sequence similarity to 
cysteine-rich domains described in MUC2 and MUC5AC. Each of the five R-
subdomains (RI-RV) has a potential N-glycosylation site and numerous potential 
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O-glycosylation sites. MUC5B is the largest mucin gene thus far described and 
the central exon of this gene is, by far, the largest reported for a vertebrate gene. 
The C-terminal region of MUC5B contains 805 amino acids, 81 of which 
are cysteine. The arrangement of cysteine residues in this sequence is very 
similar to that in the C-terminal regions of MUC2, MUC5AC and human von 
Willebrand factor (Keates et al., 1997). The C-terminal region of MUC5B has a 
04 domain, C1 and C2 domains, and a cysteine knot motif (CK) in the extreme 
C-terminal region. There are 15 potential N-glycosylation sites in the C-terminal 
region and the N-linked carbohydrates may be important for MUC5B dimerization 
(Wagner et al., 1986; Perez-Vilar et al., 1998). The stretches of hydrophobic 
amino acids in the C-terminal region may serve to bind with cholesterol and other 
lipids. 
MUC5B can form heterotypic complexes with other salivary proteins 
including amylase, proline-rich proteins, statherin and histatin (lontcheva et al., 
1997) and the complexes formed with statherin and histatin have been shown to 
occur through protein-protein interactions as opposed to carbohydrate-mediated 
interactions (lontcheva et al., 2000). Both the protein backbone of MUC5B as 
well as the carbohydrate side chains have the ability to bind microorganisms. 
Characterization of the MUC5B carbohydrate side chains revealed that these 
make a tremendously heterogeneous set of neutral, sialylated, and sulfated 
oligosaccharides, varying in length between 2 and more than 40 monosaccharide 
residues (Thomsson et al., 2002). The carbohydrate structure sulfo-Lewis (sulfo-
9 
Le) of MUC5B has recently been identified as an adhesion molecule for H. pylori 
during stress exposure (Bosch et al., 2000). The amounts of glycosylated 
variants of MUC5B can be altered significantly in disease conditions, for 
instance, an increase in the low-charge form of the MUC5B mucin in cystic 
fibrosis (CF) and chronic obstructive pulmonary disease (COPD) mucus 
(Kirkham et al., 2002) and a decrease in the relative amount of an acidic MUC5B 
glycoform during CF infection (Davies et al., 1999). MUC5B expression and 
secretion can be upregulated by bacterial stimulators and proinflammatory 
cytokines in cultured cells (Enss et al., 2000; Koo et al., 2002; Smirnova et al., 
2003) 
MUC4, the other gene product in MG1, is a membrane bound mucin. Its 
appearance in MG1 may come from the shedding of the soluble extracellular 
subunit. MUC4 will be discussed in detail in Section 11.2. 
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Figure 1: Structural organization of MUC58 
D1 D2 D3 ROI R02 RI RII RIil RIV RV D4 Cl C2 CK 
• 
Cys 1 Cys2 Cys3 Cys4 Cys5 Cys6 Cys7 
•• 
N-terminal 
1321 amino acids 
TR 
3570 amino acids 
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•• • 
C-terminal 
805 amino acids 
COOH 
Figure 1: Structural organization of MUC5B. The N-terminal region contains 
von Willebrand factor-like 01, 02 and 03 domains. The tandem repeat (TR) 
region contains alternating cysteine-rich domains (Cys1-7, white boxes) and TR 
domains (R01-V, black boxes). The C-terminal region contains a 04 domain, C1 
and C2 domains, and a cysteine knot motif (CK). 
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I1.1.b. MG2 
Low molecular weight salivary mucin (MG2) accounts for up to 70% of 
human salivary mucins (Slomiany et al., 1993d). It consists of a single 
glycosylated polypeptide chain (Tabak, 1990). The molecular weight is 130-180 
kDa (Loomis et al., 1987; Mehrotra et al., 1998; Reddy et al., 1992) and this 
mucin contains about 30% protein, 68% carbohydrate and 1.6% sulfate. Serine, 
threonine and praline constitute more than 50% of the polypeptide chain (Loomis 
et al., 1987). The carbohydrate units of MG2 are primarily O-linked glycans 
containing 2-7 residues. MG2 has been found to display a high aggregating 
activity towards a variety of bacteria colonizing the oral cavity. Its sialic acid 
residues can mediate binding with Streptococcus sanguis and are the critical 
components of the receptor site (Murray et al., 1992). The sulfated glycans are 
also important to bacterial aggregation (Piotrowski et al., 1994). Binding of the 
low molecular weight salivary mucin to A. actinomycetemcomitans , 
Staphylococcus aureus and Pseudomonas aeruginosa have been detected 
(Biesbrock et al., 1991; Groenink et al., 1998). MG2 may also provide receptors 
for the adhesion of type 1 fimbriated E. coli to oral surfaces (Moshier et al., 
1996). In addition to bacterial binding, MG2 is capable of binding Candida 
albicans and exhibits candidacidal activity (Hoffman and Haidaris, 1993; Liu et 
al., 2000). The protein backbone of MG2, especially the cysteine residues, plays 
a critical role in both bacterial binding and fungicidal activity (Situ et al., 2003). 
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The gene encoding the monomeric salivary mucin MG2 is MUC7 (Bobek 
et al., 1993). It is produced by both mucous and serous cells in human salivary 
glands (Piludu et al., 2003).The expression has been localized in submandibular, 
sublingual, labial and palatal glands (Nielsen et al., 1996). DNA sequencing 
revealed that the MUC7 gene contains a translated region of 1131 nucleotides 
encoding a protein of 377 amino acids with a molecular weight of 39 kDa (Figure 
2). The 20 N-terminal residues function as the signal peptide. The region 
encoding the secreted protein can be divided into three distinct domains: a 144 
residue N-terminal region containing two cysteine residues, a 115 or 138 residue 
central tandem repeat region containing five or six almost perfect TRs of 23 
amino acid residues with a high content of threonine (22%), serine (17%) and 
praline (35%) but no cysteine and a 75 residue C-terminal region also devoid of 
cysteine. The N-terminal and C-terminal regions contain 4 and 1 potential N-
glycosylation sites, respectively (Bobek et al., 1993). 86/105 (83%) Ser/Thr 
residues are O-glycosylated with the majority located in the tandem repeats 
(Gururaja et al., 1998). 
MUC7 is a unique mucin in the mucin family. It is the only known low 
molecular weight secreted mucin. It is not a gel-forming glycoprotein and remains 
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Figure 2: Structural organization of MUC7 
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Figure 2: Structural organization of MUC7. The N-terminal region is composed 
of 144 amino acids and contains 4 potential N-glycosylation sites. The tandem 
repeat (TR) region is composed of 138 amino acids and contains 6 perfect 
repeats (1-6). An allelic variant exists in which there are only 5 repeats. This 
region is highly O-glycosylated. The C-termin~I region is composed of 75 amino 
acids and contains 1 potential N-glycosylation site . 
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as a monomer. However, MUC7 still shares some structural characteristics with 
other mucins. It has a hydrophobic signal peptide and a TR region, which are 
also present in other secreted mucins. Its C-terminal region has a mucin-like 
amino acid composition. 
MUC7 plays an important role in the host non-immune defense system as 
an antimicrobial protein rather than as a lubricating and coating molecule. The N-
terminal 144 amino acids contain the binding site for A. actinomycetemcomitans 
(Liu et al., 2002b) and Streptococcus mutans (Liu et al., 2000). The N-terminal 51 
amino acid residues of MUC7 are the domain with candidacidal activity 
(Satyanarayana et al., 2000; Situ and Bobek, 2000). The cysteine-containing 
sequence in the N-terminal region may serve to modify interactions of MG2 with 
microbes and oral surfaces (Soares et al., 2002). MUC7 can form heterotypic 
complexes with SlgA (Biesbrock et al., 1991 }, lactoferrin (Soares et al., 2003) 
and possibly other salivary proteins. 
11.2. Membrane bound mucins in oral cavity 
The membrane-bound mucins, which are expressed on epithelial surfaces 
throughout the body, are also found in the oral cavity and the secreted forms of 
these mucins are found at low levels in saliva. These proteins are monomeric 
and are synthesized as a single polypeptide chain which is cleaved in the ER to 
generate two subunits that assemble non-covalently as a heterodimer at the cell 
surface (Ligtenberg et al., 1992b ). Both cleavage products remain associated 
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although they are not linked through disulfide bonds . The N-terminal subunit, 
which represents the actual mucin-like domain, remains indirectly anchored to 
the cell membrane as a result of its interaction with the C-terminal subunit. 
In the oral cavity, the membrane bound mucins, MUC1 and MUC4, are 
expressed in the duct epithelial cells of human major salivary glands (parotid, 
submandibular and sublingual) , minor salivary glands and oral epithelial cells (Ho 
et al., 1993; Liu et al., 1998; Offner and Troxler, 2000; Sengupta et al., 2001 ). 
Their mature products decorate the membranes of epithelial cells or are released 
proteolytically and enter the oral cavity. It is likely that the membrane-bound 
mucins have a very different functional mechanism compared with the gel-
forming mucins. 
The full-length cDNA sequence of human MUC 1 encodes a 250-400 kDa 
protein product with a variable number of TRs (Figure 3). The extracellular region 
is organized into 3 domains, an N-terminal region of 172 amino acids consisting 
of a signal peptide and a unique 107 residue sequence, a central TR containing 
420-2500 amino acids made up of 20-125 conserved 20 amino acids repeats and 
a C-terminal unique 227 residue domain . The extracellular region is followed by a 
27-residue membrane spanning domain and a 69 residue C-terminal cytoplasmic 
domain . Potential O-glycosylation sites (serines or threonines) make up more 
than one-fourth of the total amino acids (Gendler et al., 1990b). The TR region is 
extensively O-glycosylated and the deduced amino acid sequence of the C-
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Figure 3: Structural organization of MUC1 
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Figure 3: Structural organization of MUC1. MUC 1 contains a 107 residue N-
terminal region (I), an extensively O-glycosylated central tandem repeat region 
with a variable number of 20 residue tandem repeats (TR), a 227 residue C-
terminal extracellular domain (II), followed by a 27 residue trans-membrane 
domain (TM) and a 69 residue C-terminal cytoplasmic tail (CT) . MUC1 is cleaved 
in ER at the site FRPG/SWV and the two subunits, an extracellular subunit and 
a transmembrane subunit, remain non-covalently linked. 
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terminal region also contains five potential N-glycosylation sites (Gendler and 
Spicer, 1995). 
The complete MUC4 cDNA encodes a membrane-anchored mucin with a 
predicted size of 930 kDa. The deduced amino acid sequence is organized into 3 
regions: N-terminal, TR and C-terminal regions (Figure 4) (Gross et al., 1992; 
Nollet et al., 1998; Moniaux et al., 1999; Moniaux et al., 2000). 
The deduced N-terminal amino acid sequence of MUC4 has 978 residues 
and is organized into three distinct domains: a signal peptide domain, a domain 
containing three imperfect repeats enriched in threonine and serine and a 
domain corresponding to a unique sequence also enriched in threonine and 
serine. There are three cysteine residues in the signal peptide and one in the 
imperfect repeat domain. There are three potential N-glycosylation sites identified 
in the N-terminal region. 
The central TR region of MUC4 is a large domain varying in length from 
3285 to 7285 amino acid residues. It is composed of a large mucin-type domain 
characterized by the perfect repetition of 16 amino-acid residues. This region 
contains about 50% threonine and serine, 10% praline and no cysteine. 
The MUC4 C-terminal region is 1156 amino acids in length and can be 
divided into 12 distinct domains (CT1-12) with two EGF-like domains (CT7 and 
CT9), two cysteine-rich domains, a transmembrane domain and a short 
cytoplasmic tail with a potential phosphorylation site (Moniaux et al., 1999; 
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Choudhury et al., 2000). There are a total of 32 potential N-glycosylation sites in 
the C-terminal region and 28 of them are present in CT 4 and CT5. 
In situ hybridization studies have shown that MUC4 presents a very 
diverse expression pattern. It is expressed in numerous normal tissues such as 
trachea, lung, stomach, colon, uterus and prostate (Audie et al., 1993; Audie et 
al., 1995) but it is not detected in the normal pancreas, gall bladder, liver or 
biliary epithelial cells (Balague et al., 1995; Vandenhaute et al., 1997). The 
abnormal expression of MUC4 has been demonstrated to occur in several 
epithelial cancers such as lung, pancreas and gall bladder carcinoma (Nguyen et 
al., 1996; Gopin et al., 2001 ), as well as in various cancer cell lines (Balague et 
al., 1994). 
The MUC4 protein is composed of two subunits, the 850 kDa mucin-type 
subunit MUC4 alpha and the 80 kDa membrane-associated subunit MUC4 beta. 
These two subunits associate non-covalently and remain together after insertion 
into the cell membrane. In addition to the originally published sequence (sv0-
MUC4), several MUC4 cDNA sequences (called sv1-MUC4 to sv21-MUC4, 
MUC4/X, MUC4/Y) from various tissues and cell lines have been recently 
described and appear to arise by deletions and/or insertions located in the 3' 
region or by deletion of the central repetitive domain (Moniaux et al., 2000; 
Escande et al., 2002). MUC4 can be expressed in three distinct forms, one 
membrane-bound, one secreted (lacking the transmemrane domain}, and 
another secreted form lacking the tandem repeat (Moniaux et al., 2000). Different 
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MUC4 transcripts are generated by several alternative splicing mechanisms such 
as the alternative use of cassette exons or exon skipping (Escande et al., 2002). 
MUC4 is a potential activator of epithelial repair mechanisms and its 
expression can be increased by neutrophil elastase (Fischer et al., 2003). The 5'-
flanking region of MUC4 contains epithelial cell-specific regulatory cis-elements 
and the promoter of the MUC4 gene in the 5'-flanking region can be up regulated 
by epidermal growth factor, protein kinase C with phorbol ester, and transforming 
growth factor-alpha. The proinflammatory cytokines tumor necrosis factor-alpha 
and interferon (I FN)-gamma inflammatory cytokines have little or no effect on 
MUC4 transcriptional activity when used alone. However, a very strong 
synergistic effect (10-12-fold activation) between IFN-gamma and tumor necrosis 
factor-alpha or IFN-gamma and transforming growth factor-alpha has been 
observed in a MUC4 expressing pancreatic cancer cell line (Perrais et al., 2001 ). 
Altogether, these results demonstrate that regulation of MUC4 gene expression 
involves complex interplay between several signaling pathways. The 
transmembrane subunit of MUC4 contains two EGF-like domains and acts as an 
intramembrane ligand for the receptor tyrosine kinase ErbB2 (Choudhury et al., 
2000). Transfection studies with MUC4 DNAs show that MUC4 expression can 
markedly reduce both cell-cell and cell-matrix interactions in vitro and can 
increase the growth of primary tumors, possibly through the ability to suppress 
apoptosis (Carraway et al., 2000). MUC4, as a novel intramembrane ligand for 
the receptor tyrosine kinase ErbB2/HER2/Neu, triggers a specific 
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Figure 4: Structural organization of MUC4 
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Figure 4: Structural organization of MUC4. MUC4 contains a 978 residue N-
terminal region (I), an extensively O-glycosylated central tandem repeat region 
with a variable number of 16 residue tandem repeats (TR), a 1159 residue C-
terminal region containing a 432 residue domain (II), a 677 residue domain (III), 
a 25 residue trans-membrane domain (TM) and a 22 residue cytoplasmic tail 
(CT). MUC4 is cleaved in ER at the site GDPH and the two subunits, an 
extracellular subunit MUC4a and a transmembrane subunit MUC4~, remain non-
covalently linked. 
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phosphorylation of Erb82 in the absence of other ErbB ligands and potentiates 
phosphorylation and signaling through the ErbB2/ErbB3 heterodimeric receptor 
complex formed in the presence of neuregulin (Carraway et al., 2003). 
Ill. MUC1 characteristics 
111.1. MUC1 expression 
MUC1 is the first identified membrane-bound mucin. It was first cloned 
nearly simultaneously from mammary carcinoma and pancreatic tumor cDNA 
libraries (Gendler et al., 1990a; Gendler et al., 1990b; Lan et al., 1990). MUC1 
exhibits a ubiquitous distribution in most normal epithelial cells including salivary 
gland ducts and serous acini, but not mucinous acini (Liu et al., 2002a); ocular 
surface epithelia (Gipson, 2004); mammary gland acini and ducts (Patton et al., 
1995); respiratory and ciliated epithelium of the lungs , serous bronchial glands, 
but not mucinous ones (Buisine et al., 1999); squamous epithelium of the 
esophagus (Sagara et al., 1999); parietal cells, canaliculi and peptic cells of the 
stomach (Baldus et al., 1998); acini and ducts of the pancreas (Masaki et al., 
1999; Chhieng et al., 2003); bile ducts in the liver (Sasaki and Nakanuma, 1996); 
enterocytes of the duodenum (van Klinken et al., 1996), but not the large 
intestine; distal tubules of the kidney and collecting ducts, but not proximal 
tubules (Leroy et al., 2002); bladder urothelium (Walsh et al., 1994 ); prostate 
gland epithelium; resting endometrium of the uterus; rete testis; (activated) 
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mesothelium. Important tissues with no demonstrated MUC1 expression are the 
skin epithelium and all kinds of mesenchymal tissues (Hanisch and Muller, 2000). 
Although MUC1 is defined as an epithelial antigen, in 1984, Delsol et al 
reported that lymphoid cells and malignancies express MUC 1 which was also 
known as epithelial membrane antigen (EMA) (Delsol et al., 1984). The positive 
expression of MUC 1 or EMA was also demonstrated on the surface of 
monocytes and monoblasts (Leong et al., 2003) . MUC 1 was also expressed on 
the cell surface of neoplastic and nonneoplastic plasma cells, most multiple 
myeloma (MM) cells, plasmacytomas and circulating B cells as well as normal 
hematopoietic cells (Pinkus and Kurtin, 1985; Al Saati et al., 1986; Treon et al., 
1999). Fattorossi et al discovered that resting human T cells express basal levels 
of MUC1 mRNA and protein forms intracellularly but lack surface expression. 
MUC1 fulfills the criteria for an early T-cell activation marker and glycosylated 
MUC 1 forms are shed by proliferating T cells (Fattorossi et al., 2002). Agrawal et 
al reported that MUC 1 serves an immunomodulatory function for human T 
lymphocytes. Newly synthesized MUC 1 is expressed on the surface of mitogen-
activated human T cells and is also found in soluble form in the supernatants 
from cultures of mitogen-activated human T cells. After removal of the mitogenic 
stimulus from the T-cell cultures, MUC1 expression is downregulated (Agrawal et 
al., 1998b). 
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111.2. MUC1 isoforms 
MUC1 is abundantly expressed on the surface of epithelial cells in many 
tissues and their carcinomas. Biosynthetic and processing studies indicate that 
cell surface MUC1 consists of a non-covalently associated heterodimer of 
separate cytoplasmic tail and extracellular subunits. This heterodimer results 
from a single precursor proteolytically cleaved in the ER during synthesis. Due to 
the variable number of repeats and alternative splicing, a considerabley high 
number of MUC1 isoforms have been described. These include MUC1 isoform A 
(tumor specific splice variant), isoform B ("normal" MUC 1) and isoforms C, D, X, 
Y, Z, REP and SEC (Obermair et al., 2002). lsoforms A, B, C and D are the 
products of alternative splicing. lsoforms X, Y and Z lack the variable number of 
tandem repeats (VNTR). MUC1/SEC and MUC1/REP are secreted forms, which 
contain a TR array but no transmembrane domain. 
MUC 1 /REP is released from full length MUC 1 under conditions in which 
alternative splicing does not occur. The mechanism of release remains to be 
determined (Julian and Carson, 2002). There are two possibilities: dissociation 
from the heterodimer complex or a secondary cleavage (shedding). 
MUC1/SEC is also a secreted MUC1 isoform. The variant MUC1/SEC 
lacks the transmembrane and cytoplasmic sequences found in the full-length 
variant (Smorodinsky et al., 1996). MUC1/SEC mRNA is detected in normal and 
carcinoma cell lines, indicating that both shed and secreted MUC1 are likely to 
contribute to soluble forms found in culture media (Julian and Carson, 2002). On 
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the basis of immunolocalization studies, MUC1/SEC also remains associated 
with the apical epithelial surface both in tissues and in cultured cells. Both 
transmembrane MUC1 and MUC1/SEC are strikingly localized to the apical 
surface of the epithelium. They may contribute to the anti-adhesive character of 
the epithelial surface (Hey et al., 2003). 
The MUC1/Y isoform, which lacks the VNTR, is a cell membrane protein 
without mucin-like characteristics (Baruch et al., 1997). It results from alternative 
splicing and is expressed on the surface of breast cancer cells and cells of other 
epithelial malignancies (Hartman et al., 1999). After binding to an as yet 
unidentified ligand, the cytoplasmic domain undergoes phosphorylation and 
enhances tumor initiation (Baruch et al., 1999). This isoform may play an 
important role in oncogenesis. 
In humans, genetic polymorphism and differential splicing produce many 
isoforms of MUC1 which may contribute to participation in protection of the cell 
surface, modulation of cell-cell interactions, signaling, and metastasis (Obermair 
et al., 2001 ). 
111.3. MUC1 in cancer and immunoreaction 
It has been reported that incomplete glycosylation, abnormal distribution, 
and ectopic expression of mucins are characteristics of malignancy. MUC1, as a 
member of the high molecular weight mucin glycoprotein family, consists of a 
protein backbone (apomucin) and many predominantly O-linked glycans. In 
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normal glandular epithelial cells, MUC1 expression is limited to the apical surface 
bordering a lumen. In cancer cells however, polarity is lost and MUC1 expression 
is detectable all over the cell surface and overexpression is observed in many 
carcinomas. 
In each MUC 1 TR, there are five potential O-glycosylation sites. There are 
also five potential N-glycosylation sites close to the transmembrane domain. In 
normal conditions, the average number of O-glycans added to each TR is around 
2.5 (Muller et al., 1997). However, in cancer cells, the O-glycans change in both 
their sites of attachment and in their composition (Taylor-Papadimitriou et al., 
1999). The alterations in glycosylation include truncated oligosaccharide side 
chains such as the sialyl-Tn and Tn antigens (GalNAc-a-Thr/Ser) which are 
expressed frequently in many carcinomas (Byrd and Bresalier, 2004). Some of 
the available MUC1-specific monoclonal antibodies as well as cytotoxic 
lymphocytes recognize the peptide sequence, PDTR, within the tandem repeat 
portion exposed by decreased degree of glycosylation. The other well-known 
carcinoma-associated carbohydrate epitopes such as sialyl-Le(X), sialyl-Le(a), 
Le(Y), and others are often expressed when O-glycans are extended through 
core 2 branching (lrimura et al., 1999). Lesions of higher grade dysplasia express 
MUC 1 with a lower degree of normal glycosylation or a remarkable variation of 
glycosylation pattern, resulting in more tumor specific exposed peptide epitopes 
that can be recognized by their corresponding antibodies (Dabelsteen et al., 
1992; Cao et al., 1997). 
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The changes in expression and post-translational modification of MUC 1 
affect cancer cell interactions. The length of the glycans as well as the high 
density of negative charges from sialic acid may repel cells from each other and 
reduce cell aggregation (Ligtenberg et al., 1992a). The interaction with the · 
extracellular matrix is also inhibited (Wesseling et al., 1995). The resulting 
strongly reduced adhesion properties may play an important role during cancer 
invasion and metastasis (Hilkens et al., 1992; Makiguchi et al., 1996). However, 
the cell interactions may be enhanced where a specific interaction is possible. 
The TR domain of the MUC 1 mucin core protein binds to domain 1 of ICAM-1 
expressed by endothelial cells, suggesting a potential role of MUC 1- ICAM-1 
interaction in the bloodborne metastases of epithelial tumors (Regimbald et al., 
1996; Kam et al., 1998; Hayashi et al., 2001 ). The tumor-secreted MUC 1 can 
also bind E-selectin, which interferes with leukocyte attachment to E-selectin. 
This interaction could be dependent on the apoprotein size or its presentation of 
the carbohydrate epitopes of sialyl-Lewis antigens (Zhang et al., 1997; 
Fernandez-Rodriguez et al., 2001) . 
MUC1 is a paradox, having both adhesive and anti-adhesive functions, as 
well as immunostimulatory and immunosuppressive activities (Agrawal et al., 
1998a). In cancer immune suppression, soluble MUC1 from cultured epithelial 
tumor cells mediates inhibition of T lymphocyte proliferation and function by 
inducing T cell growth arrest (Agrawal et al., 1998c; Chan et al., 1999). On the 
other hand, in cancer immunostimulation, the proliferation of cytotoxic T cells 
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induced by tumor associated antigens on MUC1 promote a selective 
immunological attack on cancer cells (Dziadek and Kunz, 2004). T cells appear 
to express and secrete MUC1 following their activation (Agrawal et al., 1998a). 
The controversy may be explained partly by the adhesion/anti-adhension function 
and differences between MUC 1 antigens. For example, compared to the Tn 
antigen (GalNAca-O-Ser/Thr), the Sial-Tn-glycopeptides are nonimmunogenic 
and can circumvent recognition by the immune system (Komba et al., 2000). The 
number of epitopes may also influence the immune response. Magarian-Blander 
et al proposed that in MHC-unrestricted recognition, a large number of MUC1 TR 
epitopes is necessary to effectively engage the T cell receptor, while in the 
presence of a low number of epitopes, engagement of the CD8 co-receptor by 
MHC class I molecules may be required for completing the signal through the T 
cell receptor (Magarian-Blander et al., 1996). 
Although MUC1 has possible dual functions, it has been investigated in 
cancer immunotherapy since 1980s. Antigens in both the MUC1 peptide 
backbone and in the carbohydrate epitopes have been demonstrated to be 
susceptible targets for effective cancer treatment with monoclonal antibodies and 
vaccines (Backstrom et al., 2003; Kontani et al., 2003). Anti-MUC1 core protein 
monoclonal antibodies C595 (Hughes et al., 1997; Simms et al., 2001 ), HMFG2 
(Maraveyas et al., 1994 ), BrE-3 (Kramer et al., 1993), SM3 (Biassoni et al., 
1998), and anti-MUC1 lgG PAM4 (Gold et al., 2003) have been used in 
radioimmunotherapy for epithelial cancer and lymphoma (Treon et al., 2003). 
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Vaccines are designed to stimulate antibody and cell mediated immune 
responses against tumour cells. MUC 1 peptide liposomal vaccine (BLP25) 
(Palmer et al., 2001 ), dendritic cell (DC) fused MUC1 vaccine (Kontani et al., 
2003) and interleukin-2 (IL-2) fused MUC1 vaccine (Rochlitz et al., 2003) are 
being developed for use as vaccines in cancer patients whose tumors express 
the MUC1 antigen. These early clinical studies prove that MUC1 is an excellent 
candidate molecule for active specific immunotherapy. 
111.4. MUC1 in signal transduction 
Various domains of MUC1 have been implicated in cell adhesion, cell 
signaling, and immunoregulation. MUC1 interacts with a number of proteins 
implicated in neoplasia through both its TR and cytoplasmic domains. 
As noted above, the TR region can act as a ligand for intercellular 
adhesion molecule 1 (ICAM-1) on human umbilical vein endothelial cell 
monolayers, indicating a potential role in metastatic intravasation (Regimbald et 
al., 1996; Kam et al., 1998). A motif (SAGNGGSSL) in the cytoplasmic domain of 
MUC1 has been shown to interact with p-catenin (Yamamoto et al., 1997). MUC1 
also associates with protein kinase C delta (PKC delta) . A TOR sequence 
adjacent to the beta-catenin binding motif in the MUC 1 cytoplasmic domain 
functions as a site for PKC delta phosphorylation. Phosphorylation of MUC1 by 
PKC delta increases binding of MUC1 and beta-catenin both in vitro and in vivo 
(Ren et al., 2002). The interaction between MUC1 and p-catenin can also be 
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regulated by another factor-GSK3p (glycogen synthase kinase 3p) . GSK3p binds 
the motif STDRSPYE in the cytoplasmic tail of MUC1. The binding activity 
causes phosphorylation of the serine adjacent to praline and decreases binding 
of MUC 1 to p-catenin in vitro and in vivo (Li et al., 1998b ). The overexpression of 
MUC 1 in the absence of GSK3p disrupts the E-cadherin-p-catenin complex. 
However, overexpression of GSK3p, which decreases binding of p-catenin to 
MUC1 , restores the interaction between p-catenin and E-cadherin. MUC1 and E-
cadherin may exhibit cross talk through GSK3p-regulated binding to p-catenin , 
which plays a role in the formation of adherens junctions of mammalian epithelial 
cells by connecting E-cadherin to a-catenin and, thereby, the cytoskeleton . 
These results suggest that MUC1 expression and phosphorylation may affect E-
cadherin-mediated cell adhesion in the progression of epithelial carcinoma 
(Kondo et al., 1998). 
MUC1 can also play a role in intracellular signaling through the 
MUC1/Grb2/Sos complex (Pandey et al., 1995). The cytoplasmic tail of MUC1 
contains several potential tyrosine phosphorylation sites and the tyrosine 
phosphorylation site pYTNP site directly interacts with the SH2 domain of the 
adaptor protein Grb2. Another phosphorylation of MUC1 is mediated by the 
epidermal growth factor receptor (EGFR) at a YEKV motif in the cytoplasmic 
domain and can induce interaction of MUC 1 with the c-Src non receptor tyrosine 
kinase. EGFR-mediated phosphorylation of MUC1 induces binding of MUC1 to 
the c-Src SH2 domain in cells (Li et al., 2001 ). The MUC 1 /Grb2 complex 
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associates with the guanine nucleotide exchange protein Sos because Sos binds 
to the SH3 domains of Grb2. Thereby, the complex associates with Ras through 
Sos and activates the cascade of mitogen-activated protein (MAP) kinases 
(Schroeder et al., 2001). The downstream activation of ERK1/2 can translocate 
to the nucleus and induce transcription of a variety of genes involved in 
mitogenesis, differentiation, apoptosis, and quiescence. The increased MAPK 
activity negatively regulates tight junction formation (Chen et al., 2000) and 
therefore, decreases cellular adhesion. Interestingly, ligand-independent 
activation of EGFR and subsequent downstream activation of MAPK has been 
recently described (Pece and Gutkind, 2000) through interactions with E-
cadherin. 
Treatment with heregulin/neuregulin-1 (HRG) increases the formation of 
MUC1/EGFR complexes, induces binding of MUC1 with the Wnt effector 
gamma-catenin and targeting of the MUC1-gamma-catenin complex to the 
nucleolus in human breast carcinomas but not in normal mammary ductal 
epithelium (Li et al., 2003c). These findings demonstrate that MUC1 functions in 
both EGFR and Wnt pathways by acting as a shuttle for HRG-induced nucleolar 
targeting of gamma-catenin (Li et al., 2003c). Taken together, EGFR stimulation 
induces phosphorylation of MUC1 on Tyr46 and thereby integrates intercellular 
signaling among the p-catenin and E-cadherin pathways and intracellular 
signaling through c-Src to MAP kinase pathways. 
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111.5. MUC1 in transcriptional regulation 
The promoter region of MUC 1 shows many conserved regions that could 
function as transcription factor binding sites (Vos et al., 1991 ). An Sp1 site at -
99/-90 and an E box (E-MUC 1) at -84/-64 in this region have been shown by 
mutational analysis to play a role in the regulation of transcription (Kovarik et al., 
1993). The importance of the Sp1 transcription factor is confirmed by 
demonstrating that overexpression of Sp1 in MUC1-nonexpressing cells 
increased not only the expression of a reporter gene driven by the 1.4-kb MUC1 
promoter, but also the expression of MUC 1 from the endogenous gene. 
Together, these data define an important role for Sp 1 in the cell type-specific 
transcription of MUC1 (Morris and Taylor-Papadimitriou, 2001). MUC1 is also 
repressed by the transcription factor Snail mediated by two E-boxes present in 
the proximal promoter (Guaita et al., 2002). Other studies show that the regions 
between -152 and -66, -119 and -62, -101 and -89 (Vos et al., 1991), -598 and 
--485, -505 and --485 (Abe and Kufe, 1993) of the MUC1 promoter may have 
transcriptional activity in MUC 1-expressing cells. 
The MUC 1 promoter also contains a candidate binding site for 
transcription factors of the STAT family approximately 500 base pairs upstream 
of the transcription start site. The STAT-binding site is among the elements that 
are involved in the overexpression of MUC 1 in tumor cells. Cytokines and/or 
growth factors such as interleukin-6 or IFN-gamma can activate STATs 
(Gaemers et al., 2001 ). Lagow and Carson have shown that synergistic 
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stimulation of MUC1 expression by TNF-alpha and IFN-gamma is mediated by 
independent actions of NFkappaB p65 and STAT1alpha upon NFkappaB and 
STAT sites, respectively, in the MUC1 promoter. An NFkappaB site at -589/-580 
and the STAT-binding element at -503/-495 are required for cooperative 
stimulation by TNFalpha and IFN-gamma (Lagow and Carson, 2002). Other 
proinflammatory cytokines as well as bacterial infection may also contribute to 
increased MUC1 transcription (Li et al., 2003a). IL-7 treatment is associated with 
binding of MUC1 to beta-catenin and targeting of the MUC1-beta-catenin 
complex to the nucleus, which suggests that MUC 1 itself is a potential signaling 
molecule (Li et al., 2003b). 
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Objectives 
1) To confirm the expression of membrane bound mucin MUC1 in oral 
epithelial cells. 
2) To determine whether the membrane-bound mucin MUC1 can form 
complexes with the secreted mucin MUC58 and to localize the MUC 1 
binding sites on the MUC58 polypeptide backbone. 
3) To identify other proteins from a salivary protein pool which can form 
heterotypic complexes with MUC 1 
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Materials and Methods 
Part 1. Expression of membrane bound mucin MUC1 in oral epithelial cells 
1.1. Cell collection 
At the beginning of this and subsequent sections, a list is given of the buffers and 
reagents used. 
PBS (137 mM NaCl, 2.7 mM KCI, 10 mM Na2HPO4, 2 mM KH2PO4) 
8 g NaCl 
0.2 g KCI 
1.44 g Na2HPO4 
0.24 g KH2PO4 
Adjust pH to 7.4 
Add H2O to 1 liter 
Epithelial cells from six healthy volunteers were removed from buccal 
surfaces using sterile polyethylene cell scrapers (Costar, Corning Inc, NY) after 
oral rinse with water. The cells from the first scraping were discarded. Cells from 
the second to fourth scraping were dispersed in sterile siliconated tubes 
containing 10-ml sterile phosphate-buffered saline (PBS). The cells were 
centrifuged at 1300 x g for 20 min at 4°C and washed three times with ice-cold 
PBS. 
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1.2. RNA isolation from buccal epithelial cells 
Total RNA was isolated from the collected buccal epithelial cells (BEC) 
with 1 ml Tripure reagent (Roche, Indianapolis, IN). The cell lysates were passed 
through a pipette several times and chloroform (1/5 volume) was added for the 
initial homogenization. The mixture was incubated at room temperature for 10 
min and centrifuged at 12,000 x g for 15 min. The upper aqueous phase was 
transferred to a new polypropylene centrifuge tube and 0.5 ml isopropanol was 
added. The mixture was incubated for 10 min at room temperature to allow the 
RNA precipitate to form. The RNA pellet was recovered by centrifuging at 12,000 
x g for 10 min at 4°C, washed with 1 ml 75% ethanol, air dried and resuspended 
in 20 µI diethyl pyrocarbonate (DEPC)-treated RNase-free water. The solution 
was incubated at 60°C for 1 0 min. 
1.3. RNA quantification 
To quantify the isolated RNA, RNA samples were measured at a 
wavelength of 260 nm using a Perkin-Elmer Lambda 2 UV-Visible 
spectrophotometer (Perkin-Elmer, Norwalk, CT). An absorbance of 1.0 at 260 nm 
equals 40 ng/µI of RNA. The ratio of 00 260/00 280 showed the purity of nucleic 
acid from the contamination of protein or Tripure reagent phenol. Ideally, a pure 
preparation of RNA has a ratio of 2.0. The isolated RNA samples from above (4 
ul) were diluted into 1 ml H20 in a cuvette with a path length of 10 mm and the 
concentration was calculated as: 00 260 x 40 ng/µI x dilution factor. 
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1.4. Reverse transcriptase-polymerase chain reaction (RT-PCR) 
RNA samples (5 µg) were denatured at 60 °C for 10 min and chilled on ice 
for 2 min. First-strand cDNA was synthesized in the presence of 5 µg RNA, 1 µI 
10 mM dNTP (Promega, Madison, WI), 100 pmol random hexamer primers 
(Amersham, Chicago, IL), 4 µI 5 x first-strand buffer, 1 µI 0.1 M OTT, 0.5 µI 
RNAse inhibitor (Promega), and 2 µI M-MLV Reverse Transcriptase (lnvitrogen, 
Carlsbad, CA) in 20 µI reactions. The mixture was incubated for 1 hat 37°C. 
PCR amplication was carried out under standard conditions (35 cycles of 
30 sec at 94°C, 45 sec at 55°C, 60 sec at 72°C). Every 50 µI mixture contained 1 
µI cDNA, 5 µI 10 x PCR buffer, 3 µI 25 mM MgCb, 1 µI 10 mM dNTPs, 10 pmol 
each sense and anti-sense primer, and 2.5 U Taq polymerase (Promega). 
The primers were derived from sequences in the non-tandem repeat region of 
MUC 1 and were designed to span intron/extron boundaries. The sense and anti-
sense primers used to generate a 207 bp MUC 1 am pl icon were: 
MUC1 sense: 5' CGCCGAAAGAACTACGGGCAGCTG 3' 
MUC1 anti-sense: 5' CAAGTTGGCAGAAGTGGCTGCCAC 3'. 
1.5. DNA agarose gel electrophoresis: 
50 x T AE buffer: 
242 g Tris base 
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57 .1 ml Glacial acetic acid 
100 ml 0.5 M EDTA (pH 8.0) 
6 x DNA Gel Loading Buffer: 
0.25% Bromophenol Blue 
0.25% Xylene Cyanol 
30% Glycerol 
The 50 x TAE buffer was diluted to 1 x TAE with water and 0.5 µg/ml 
ethidium bromide (EB) was added into the diluted solution to make the gel 
running buffer. The 1 % agarose gels were prepared with running buffer. The 6 X 
DNA gel loading buffer was mixed with DNA samples to give a final concentration 
of 1 x. Then, DNA samples were electrophoresed in the running buffer at 100 
volts, using an electrophoresis chamber (Horizon® 58, Life Technology), until the 
dye makers migrated to an appropriate distance. A 1 kb DNA Ladder (lnvitrogen) 
was used in every gel as a molecular weight marker. After electrophoresis, gels 
were examined on a Dual Intensity UV Transilluminator (UVP, San Gabriel, CA) 
and photographs were taken with a Polaroid DS-34 Direct Screen Instant 
Camera . 
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1.6. Preparation of cell lysates 
RIPA buffer: 
1 x PBS 
1 % Nonidet P-40 
0.1% sos 
0.5% Sodium deoxycholate 
The SEC were lysed in RIPA buffer on ice for 45 min on a rocker platform 
and the cell lysates were passed through a 21 gauge needle to shear the DNA. 
After centrifugation at 10,000 x g for 15 min at 4°C, the supernatants were 
collected into new tubes. Both the supernatants and the cell pellets were saved 
for Western blotting. 
Cell lysates from human oral epidermoid carcinoma KB cells and 
fibroblast-like COS-7 cells (ATCC, Rockville, MD) were used as positive and 
negative controls, respectively. 
1. 7. Western Blotting using the Tris-Tricine Buffer method 
Tris/SOS: 
3M Tris-HCI, pH 8.45 
0.3% sos 
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10% Tricine SDS separating gel: 
1.63 ml 30% Acrylamide (29.2% acrylamide, 0.8% N,N'-methylene-bis-
acrylamide) 
1.66 ml Tris/SOS, pH 8.45 
1.17 ml H20 
0.66 g (0.53 ml) Glycerol 
50 µ110% Ammonium persulphate 
2 µI TEMEO 
Tricine SDS Stacking gel: 
0.27 ml 30% Acrylamide 
0.5 ml Tris/SOS, pH 8.45 
1.3 ml H20 
20 µI 10% Ammonium persulphate 
2 µI TEMEO 
2 x Tricine sample buffer: 
1 ml 0.5 M Tris-HCI, 0.4% SOS, pH 6.8 
3 g (2.4 ml) Glycerol 
0.8 g sos 
0.31 g OTT 
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2 mg Coomassie brilliant blue G-250 
Make up to 10 ml with H2O 
Cathode buffer: 
12.11 g Tris base (0.1 M) 
17.92 g Tricine (0.1 M) 
1 g sos (1%) 
Dilute to 1 L with H2O 
Anode buffer: 
24.22 g Tris base (0.2 M), pH to 8.9 
Make up to 1 L with H2O 
PBST: 
1 x PBS 
0.05% Tween 20 
Proteins from both the BEC lysate supernatant and the cell pellet were 
analyzed on 10% Tricine SOS gels in a Bio-Rad Mini Gel System. Proteins were 
eletrophoresed at 1 00v and transferred to nitrocellulose membrane. The 
membrane was blocked for 1 h at room temperature in 5% non-fat dry milk 
dissolved in PBST, and probed with a hamster monoclonal antibody directed 
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against a peptide sequence in the cytoplasmic tail of MUC1. This antibody, CT-2, 
was used at a dilution of 1 :300 and was kindly provided by Dr. Sandra Gendler, 
Mayo Clinic, Scottsdale, AZ, USA. After a 1 h incubation at room temperature, 
the blot was washed with PBST 4 x 5 min. Following incubation with secondary 
HRP-conjugated hamster-specific antibody (1 :100,000) and washing as above, 
the blot was developed with enhanced chemiluminescence reagent (Perkin 
Elmer, Boston, MA, USA) and exposed to X-ray film (Marsh Bio Products, 
Rochester, NY, USA). 
1.8. lmmunohistochemistry (IHC) 
The expression pattern of MUC 1 was investigated in buccal smears, 
buccal mucosa! tissue and gingival tissue by IHC using a monoclonal antibody 
clone E29 purchased from NeoMarkers (Fremont, CA, USA). The slides were 
analyzed using a Nikon OPTIPHOT microscope attached to an RT color SPORT 
camera and the SPORT Advanced software (Diagnostic instruments, Inc, Detroit, 
Ml) at 1 OOX, 200X and 400X magnification. 
Buccal smears from healthy volunteers were prepared fresh immediately 
prior to performing IHC. The smears on glass slides were air-dried, fixed in 
acetone for 5 min and washed three times with PBS for 5 min. The endogenous 
peroxidase activity was quenched using 0.3% H20 2 in 100% methanol for 15 min 
at room temperature and washed three times with PBS for 2 min. The slides 
were incubated with 2.5% horse serum (Vector, Burlingame, CA, USA) at 37°C 
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for 30 min in a humidified chamber to block non-specific binding sites. Then they 
were incubated with primary antibody E29 (1 :50) diluted with 3% BSA in PBST at 
37°C for 1 h. After rinsing, slides were incubated with biotinylated "universal " 
secondary antibody (Vector) at 37°C for 30 min and washed three times with 
PBS for 5 min. Slides were then incubated with R.T.U. Vectastain Elite ABC 
reagent (Vector, at 37°C for 30 min, washed as above and color was developed 
with DAB solution (Vector) at room temperature . Slides were counterstained with 
0.68% hematoxylin and examined by light microscopy . Control experiments were 
carried out in which incubation with the primary antibody was omitted. 
Five sections of paraffin-embedded specimens of normal buccal mucosa 
on glass slides were kindly provided by Dr. Sadru Kabani in the Department of 
Oral Pathology at the Boston University Goldman School of Dental Medicine. 
Each slide contained the complete buccal epithelium with underlying connective 
tissue and minor salivary glands . Dr. Kabani confirmed that there was no 
dysplasia, carcinoma in situ or carcinoma in these tissues. No further information 
about the patients was provided. Sections were deparaffinized in xylene, 
rehydrated using a graded ethanol series (100% to 70%) and washed with PBS. 
Antigen retrieval was carried out by microwaving the slides in 10 mM sodium 
citrate (pH 6.0) for 15 min and cooling at room temperature for 20 min. The 
blockage of endogenous peroxidase activity, incubation with antibody, color 
development and staining were performed as described above. 
47 
Gingival tissues were taken at periodontal surgery from an adult patient 
with severe periodontitis and the samples were kindly provided by Dr. Serge 
Dibart, Department of Periodontology and Oral Biology, Boston University, 
Goldman School of Dental Medicine. Samples were first frozen in liquid nitrogen 
and frozen sections were made. For the detection of MUC1, frozen tissue 
sections were fixed in acetone for 5 min. Endogenous peroxidase activity was 
blocked and antigen retrieval was achieved as above. Antibody incubation, color 
development and staining were also performed as above. 
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Part 2. Protein-protein interaction between MUC1 and MUC58 
2.1. Construction and cloning of MUC1-N terminal recombinant protein 
(GST-M1) 
2.1.a. RNA isolation and quantification from submandibular gland 
The technique used for RNA isolation from human submandibular gland 
tissue was the same as that used for RNA isolation from BEC. Human 
submandibular gland tissue was obtained from the National Disease Research 
Interchange (Philadelphia, PA). Frozen tissue samples (1 g) were suspended in 
10 ml TriPure reagent and homogenized in a polytron. Chloroform (115th volume) 
was added and the phases were allowed to separate. After centrifugation for 15 
min at 10,000 x g, the upper aqueous phase was removed and RNA was 
precipitated with isopropanol. The RNA pellet was recovered, washed with 70% 
ethanol, air dried, and dissolved in nuclease-free water. The concentration of 
human submandibular gland RNA was determined spectrophotometrically as 
described above. 
2.1.b. Reverse transcriptase-polymerase chain reaction (RT-PCR) 
Submandibular gland RNA samples (5 µg) were denatured at 65°C for 10 
min and chilled on ice. The final composition of the 20µ1 reaction mixture was: 1 x 
first strand buffer, 5 mM OTT, 1 mM dNTPs, 50 pmol random primer, 10 U 
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RNAsin (Promega), 200 U reverse transcriptase (lnvitrogen). The reaction was 
incubated for 1 h at 37°C. 
Sequences encoding the N-terminal fragment of MUC1 (MUC1 N), 
corresponding to residues 1 to 107, was amplified by PCR. Reactions were 
carried out in a total volume of 50 µI with 1 µI cDNA template, 1 x PCR buffer, 1.5 
mM MgCl2, 0.2 mM dNTPs, 2.5 U Taq polymerase (Promega), and 10 pmol each 
of the sense and antisense primers. The cycling parameters were 5 min at 95°C 
for initial denaturation, followed by 35 cycles of 1 min at 95°C for denaturation, 45 
sec at 58°C for annealing, 1.5 min at 72°C for extension, and a final extension 
step at 72°C for 1 0 min. The sense and anti-sense primers were designed with a 
BamH 1 restriction site and an Xho1 site at the 5' end of each, respectively 
(italicized below). The sequences of these primers were: 
MUC1N sense: 5' CGGGATCCGCACAGGTTCTGGTCATGCAAG 3' 
MUC1N anti-sense: 5' AACTCGAGACGGGGCTGGCTTGTTGTC 3' 
2.1.c. Gel electrophoresis and purification 
PCR products were examined on 1 % agarose-TAE gels as described 
above. For cloning, PCR products of the expected size (321 bp). were excised 
from the gel using a razor blade and were purified using Qiagen's QIAquick Gel 
Extraction Kit. 
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2.1.d. Restriction digestion and ligation 
The purified MUC 1 N DNA fragment was digested with the restriction 
enzymes BamH1 and Xho1. The prokaryotic expression vector pGEX-5X-2 
(Amersham) was also digested with the same enzymes. The 50 µI digestion 
reaction contained 2 µg recovered DNA or vector, 25U BamH1, 25U Xho1, and 
1 x buffer B (Promega). The reactions were carried out at 37°C for 4-16 hours. 
After digestion, reaction mixtures were electrophoresed, bands containing the 
insert and vector were cut from the agarose gel and DNA was purified from the 
gel slices as described above. An aliquot (5-10%) of each recovered sample was 
electrophoresed and the intensity of the DNA band was used to estimate 
concentration. Ligation reactions were then performed using a 1 :3 molar ratio of 
vector and insert with 1 x T 4 DNA ligation buffer, 3U of T 4 DNA ligase (Promega), 
and H20 in a total volume of 15 µI. The ligation reactions were incubated at 12°C 
overnight or at room temperature for 3 h. The MUC1 N-terminal DNA fragment 
was cloned in frame downstream of the glutathione-S-transferase (GST) fusion 
partner in pGEX-5X-2. 
2.1.e. Transformation into bacterial cells 
LB medium: 
10.0 g Tryptone 
5. 0 g Yeast extract 
51 
10.0 g NaCl 
Make up to 1 L with distilled water, adjust pH to 7.0 and autoclave 
LB/ampicillin (LBA) medium: 
1 ml of 100 mg/ml Ampicillin stock per liter LB medium 
LB/ampicillin (LBA) plate: 
10.0 g Tryptone 
5.0 g Yeast extract 
10.0 g NaCl 
15.0 g Agar 
Make up to 1 L with distilled water, adjust pH to 7.0 and autoclave 
Cool the medium to 50°C 
Add 1 ml of 100 mg/ml Ampicillin stock 
Mix and pour into petri dishes (about 25 ml / 100 mm dish) 
The ligation reactions were used to transform competent E.coli JM109 
cells (Promega). Briefly, 2.5 µI of the ligation reaction was added into a 
microcentrifuge tube containing 50 µI JM 109 cells without mixing. The tube was 
chilled on ice for 30 min and heated at 42°C in a water bath for 45 sec without 
shaking. After cooling on ice for 2 min, 250 ml room temperature SOC medium 
(Novagen, San Diego, CA) was added and the tube was incubated at 37°C for 1 
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h with shaking at 200 rpm. Aliquots of the transformation reaction (50 and 200µ1) 
were spread onto LB/ampicillin plates and the plates were incubated at 37°C 
overnight. Colonies containing MUC1 N inserts were identified by colony PCR 
using pGEX forward and reverse primers. After several hours of re-growth, 
remnants of colonies containing MUC 1 N inserts were used to inoculate cultures 
containing 50 ml LB/ampicillin medium. Bacterial cells were grown overnight at 
37°C with shaking at 225 rpm and plasmid DNA was purified using the Qiagen 
Plamid Midi Protocol and sequenced at the Genetics Core at Boston University 
Medical Center. Plasmid DNA (1 Ong) with the correct sequence was used to 
transform 20 µI E. coli BL21 cells (Novagen) for expression of the GST-M1 
recombinant protein . The JM109 competent cells were used for selection of DNA 
plasmid and BL21 cells were chosen for high level of protein expression. Empty 
vector pGEX-5X-2 was also transformed into BL21 cells to express the GST 
control protein . 
2.1.f. Protein expression in bacterial cells 
2 x YT-G medium: 
5 g NaCl 
10 g Yeast extract 
16 g T ryptone 
Make up to 900 ml, adjust pH to 7.0 , autoclave 
53 
Cool the medium to 50°C 
Aseptically add 100 ml of sterile 20% glucose 
6 X SOS Loading buffer: 
0.35 M Tris-HCI, pH 6.8 
36% (v/v) Glycerol 
10.28% (w/v) SOS 
5% ~-mercaptoethanol 
0.012% (w/v) Bromophenol blue 
Store in 0.5 ml aliquots at -80°C 
8% SDS-Polyacrylamide Gel (5 ml): 
2.3 ml H20 
1.3 ml 30% Acrylamide mix 
1.3 ml 1.5 M Tris-HCI, pH 8.8 
0.05 ml 10% SOS 
0.05 ml 10% Ammonium persulphate 
0.003 ml TEMED 
SDS-Polyacrylamide Stacking Gel (2 ml): 
1.4 ml H20 
0.33 ml 30% Acrylamide mix 
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0.25 ml 1.0 M Tris-HCI, pH 6.8 
0.02 ml 10% SOS 
0.02 ml 10% Ammonium persulphate 
0.002 ml TEMED 
Tris/Glycine SDS-PAGE Running Buffer: 
12.11 g Tris base 
57 .6 g Glycine 
4g sos 
Make up to 4 L with H2O 
Tris/Glycine SDS-PAGE Blotting Buffer: 
11.6 g Glycine 
23.3 g Tris base 
1.48 g sos 
800 ml Methanol 
Make up to 4 L with H2O 
Coomassie Blue Staining Solution: 
0.25 g Coomassie Brilliant Blue R250 
450 ml Deionized water 
450 ml Methanol 
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100 ml Glacial acetic acid 
Coomassie Blue Destain Solution: 
500 ml Deionized water 
400 ml Methanol 
100 ml Glacial acetic acid 
A small-scale pilot experiment was done to check and establish the 
optimal conditions for bacterial protein expression . A single colony of E. coli 
BL21 cells containing the recombinant GST-M 1 plasmid was picked up and used 
to inoculate 5 ml of 2 x YT-G medium containing 100 µg/ml ampicillin. The culture 
was incubated at 37°C for 12-15 h with vigorous shaking at 200 rpm. Then, the 
culture was diluted 1 :50 into 5 ml fresh 2 x YT-G medium containing 100 µg/ml 
ampicillin and grown under the same conditions for about 2-3 h until the A500 
reached 1-2. An aliquot (1 ml) of the culture was removed and centrifuged at 
14,000 rpm for 5 min. The supernatant was discarded and the pellet was 
immediately frozen. To induce protein expression, 100 mM IPTG was added to 
the remainder of the culture to a final concentration of 0.1 mM. Incubation was 
continued for an additional 3 h at 37°C or 30°C. During the induction period, 1 ml 
aliquots were removed at the end of each hour from the culture and centrifuged 
at 14,000 rpm for 5 min. In each case, cell pellets were immediately frozen . Cell 
pellets from all time points were boiled in 100 µI 1 x SOS loading buffer for 5 min, 
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centrifuged briefly to remove insoluble material and the supernatants 
electrophoresed on 8% SDS-polyacrylamide gels. Gels containing the samples 
above were stained with Coomassie Brilliant Blue R-250 for 1 h at room 
temperature and destained with several changes of destain solution to remove 
the background color. 
A single colony containing the pGEX-5X-2 control plasmid was used to 
induce the GST control protein under the same conditions. 
2.1.g. Large Scale protein purification from cell culture 
Glutathione Binding Buffer: 
1 x PBS, pH 7.3 
Glutathione Elution Buffer: 
1 0mM reduced Glutathione 
50mM Tris-HCI 
Adjust pH to 8.0 
Based on results of the small scale pilot experiments, 500 ml of 2 x YT-
G/ampicillin medium was inoculated with 20 ml of an overnight culture. After the 
induction of GST-M1 fusion protein expression, cell cultures were transferred to 
500 ml centrifuge bottles and centrifuged at 8,000 rpm for 10 min at 4°C to 
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sediment the cells. Cell pellets were completely suspended in 25 ml ice-cold 1 x 
PBS. A solution of 20% Triton X-100 was added to a finial concentration of 1 %. 
The suspension was mixed in an ice water bath on a rocker for 30 min to help 
solubilize the cell membrane. Then, the suspension was sonicated on ice with a 
Branson Sonifier 450 (VWR Scientific, Danbury, CT, USA) to disrupt the cells in 2 
x 24 bursts of 4 sec at a 40% duty cycle. After centrifugation at 10,000 rpm for 10 
min at 4°C, the supernatant was transferred to a new tube. A 1 ml GSTrap TM 
column (Amersham) was connected with pump adaptors and equilibrated with 5 
volumes of glutathione binding buffer. The samples were pumped onto the 
column using a flow rate of 0.2 ml/min (Pump P-1, Pharmacia Biotech) and 
washed with 10 ml of binding buffer at the flow rate of 1 ml/min. The GST-M1 
fusion protein was eluted by pumping 10ml glutathione elution buffer at a flow 
rate of 1 ml/min . The elution was collected in 1 ml fractions and the absorbance 
of each fraction at 280 nm was measured. Fractions with highest absorbance 
were collected, dialyzed against distilled water and lyophilized. The purified GST-
M1 fusion protein was dissolved in water and the protein concentration was 
measured by BCATM protein assay (Pierce, Rockford, IL, USA). 
The GST control protein was prepared at the same time under identical 
conditions. 
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2.2. GST pull down assays 
Simulated Saliva Buffer (558): 
2.6 mM sodium phosphate 
6.3 mM sodium chloride 
0.6 mM calcium chloride 
Adjust pH to 7.5 
The high molecular weight mucin MG1 (referred to as MUC58) was 
isolated from human submandibular/sublingual secretion and was a generous gift 
of Dr. Robert Troxler. GST-M1 fusion protein or GST control protein (10 ug) was 
incubated with MUC58 (4 µg) in 500 µI SSB in 1.5 ml centrifuge tuces on an end-
to-end rocker at 4°C for 12-16 h. For each protein, 50 µI of a 50% slurry of 
Glutathione Sepharose 48 was added to the tube after equilibration of the resin 
with 1 x PBS. The mixtures were incubated at room temperature for 1 h to allow 
binding of GST to the resin and were centrifuged at 500 x g for 5 min. The 
supernatant was removed and the resin pellet was washed 4 times with 1 ml 
PBST. Bound proteins were dissociated in 30 µI 2 x SOS loading buffer and 
boiled for 5 min before they were examined on 6% SOS-gels. Gel electrophoresis 
was performed as described above and Western blotting was carried out 
according to the standard protocol. Briefly, the proteins were electrophoresed on 
a 6% acrylamide SOS-gel and transferred to a nitrocellulose membrane. The 
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membrane was blocked with 5% milk in PBS and incubated with rabbit polyclonal 
anti-MUC5B antibody (1: 1000). The second antibody was HRP-conjugated goat 
anti-rabbit lgG (1 :7500). The immunoreactive bands were visualized with 
enhanced chemiluminescence reagent (Perkin Elmer, Boston, MA, USA). 
2.3. Far Western Blotting of MUC1 and MUC5B 
Basic Buffer: 
20 mM HEPES, pH 7.5 
50 mM KCI 
10 mM MgCb 
1 mM OTT 
0.1 % Nonidet P-40 
Blocking Buffer: 5% milk in Basic Buffer 
Interaction buffer: 1 % milk in Basic Buffer 
Wash Buffer 1: PBS containing 0.2% Triton X-100 
Wash Buffer 2: PBS containing 0.2 % Triton X-100 and 100 mM KCI. 
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Samples of GST-M 1 fusion protein and GST control protein (6 µg) were 
electrophoresed on 12% SOS gels and proteins were transferred to nitrocellulose 
membrane. Blots were equilibrated with Basic Buffer for 10 min at 4°C and 
blocked with 5% milk in Basic Buffer for 4 h at 4°C. Then, the membrane was 
incubated in 10 ml of Interaction buffer containing MUC5B (1.6 µg) overnight at 
4°C with gentle agitation. Subsequently, blots were washed 4 times with wash 
buffer 1 and 2 times with wash buffer 2, each wash was carried out at 4 °C for 10 
min. Next, the blots were incubated with rabbit polyclonal anti-MUC5B antibody 
(1: 1000) and HRP-conjugated goat anti-rabbit lgG (1 :7500) as in standard 
Western blotting. lmmunoreactive bands were visualized with enhanced 
chemiluminescence reagent as described above. 
2.4. Yeast two hybrid screens 
2.4.a. Construction of DNA-BO and DNA-AD fusions 
Constructs encoding the N-terminal 107 residues of MUC1 were prepared 
in the yeast binding domain (BO) bait vector pGBKT7 (Clontech, Palo Alto, CA, 
USA). 
As described above, the MUC 1 N-terminal DNA fragment (residue 1-107) 
was amplified from cDNA which was reverse transcribed from submandibular 
gland RNA. The sense and anti-sense primers containing Nde1 and Pst1 
restriction sites, respectively (italics), are shown below: 
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BD-M1-I sense: 5' GGCGGCCGACATATGACAGGTTCTGGTCATGCA 3' 
BD-M1-I anti-sense: 5' ATATCTGCAGCGGGGCTGGCTTGTTGTCCG 3' 
The yeast DNA-BO bait vector pGBKT7 was digested with Nde1 and Pst1. 
Then the MUC 1 N-terminal PCR fragment was ligated with the digested vector, 
transformed into E.coli strain JM109 and the transformation reaction plated on LB 
plates containing kanamycin. Colonies containing MUC1 N inserts were identified 
by colony PCR using the T7 and 3' DNA-BO sequencing primers. 
T7 forward primer: 5' TAATACGACTCACTATAGGG 3' 
BO reverse primer: 5' TAAGAGTCACTTTAAAATTTGTAT 3' 
Colonies containing inserts of the expected size were selected to inoculate 
cultures containing 50 ml LB/kanamycin medium. DNA plasmids were purified 
using the Qiagen Plamid Midi Protocol and plasmid DNA was sequenced at the 
Genetics Core at Boston University Medical Center. Constructs encoding 
individual MUC5B domains were prepared in the yeast activation domain (AD) 
prey vector pGADT7 (Clontech). 
As described above, MUC5B DNA fragments were amplified from 
submandibular gland cDNA using specific primers. The fragments were: the D3 
domain from the MUC5B N-terminal region (residue 893-1249), and the D4, C1, 
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C2, and CK domains from the MUC5B C-terminal region (residue 292-632, 643-
706, 7 44-808, and 829-983, respectively). The sense and anti-sense primers 
containing EcoR1 and Xho1 restriction sites, respectively, are shown in Table 1. 
The yeast DNA-AD vector pGADT7 was digested with EcoR1 and Xho1. 
Then, each of the MUC5B DNA fragments was ligated with the digested vector, 
transformed into E.coli strain JM109 and the transformation reactions were 
plated on LB plates containing ampicillin. Colonies containing MUC5B inserts 
were identified by colony PCR using the T7 sequencing primer and the 3' DNA-
AD sequencing primer (5'AGATGGTGCACGATGCACAG3'). Colonies containing 
inserts of the expected size were selected to inoculate cultures containing 50 ml 
LB/ampicillin medium. DNA plasmids were purified using the Qiagen Plamid Midi 
Protocol and plasmid DNA was sequenced at the Genetics Core at Boston 
University Medical Center. 
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Table 1: Sense and anti-sense primers for MUC5B domains a 
03 Sense 5'ATAGAA TTCACCTGCGTGGCCTACGGGGATGGC3' 
Anti-sense 5'AGACTCGAGCTGGATGCCACTGGGTGTGCAGTT3' 
04 Sense 5'CTCAGCGAATTCTGCATCTGCAGCATGTGGGGC3' 
Anti-sense 5'TCGT CTCGA GGGCCTGCACGCAGATGCCCAT3' 
C1 Sense 5'ACTAGTAGAA TTCTGCCCCTGCGTGGGACCCGAT3' 
Anti-sense 5'GATCTCGAGGCACACGCACACCGTCTCGGGGCA3' 
C2 Sense 5'CTCAGCGAATTCTGTTCGTACAA TGGCACC3' 
Anti-sense 5'TCGTCTCGAGGACGCACTCCCCACAGCACTG3' 
CK Sense 5'CTCAGCGAA TTCAGCCATGTGGACAACTGCACC3' 
Anti-sense 5'TCGT CTCGA GGACAGCAGTGGCCTCA TCCAC3' 
a. All sense primers contain an EcoR1 site (italics) and all anti-sense primers 
contain an Xho1 site (italics). 
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2.4.b. Preparation of competent yeast cells 
YPDA medium: 
20 g/L Difeo peptone 
10 g/L Yeast extract 
Add water to 935 ml, adjust pH to 5.8, and autoclave 
Cool to 55°C, add 50 ml of sterile 40% glucose (dextrose) and 15 ml of a 0.2% 
solution of adenine hemisulfate . 
YPDA plates: 
20 g/L Difeo peptone 
10 g/L Yeast extract 
20 g/L Agar 
Add water to 935 ml, adjust pH to 5.8, and autoclave 
Cool to 55°C, add 50 ml of sterile 40% glucose (dextrose) and 15 ml of a 0.2% 
solution of adenine hemisulfate solution 
Mix and pour into petri dishes 
PEG/LiAc solution: 
8 ml 50% Polyethylene glycol (PEG 3350) 
1 ml 10 x TE buffer 
1 ml 10 x LiAc (1M) 
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The solution was made fresh just prior to transformation 
1.1 x TE/LiAc solution: 
1.2 ml 10 x TE 
1.1 ml 10 x LiAc (1M) 
Add water to 10 ml 
A small portion of frozen yeast stock AH 109 (Clontech) was streaked onto 
a YPDA plate and the plate was incubated at 30°C for about 3 days until colonies 
appeared. One colony approximately 2-3 mm in diameter was inoculated into 3 
ml of YPDA medium in a sterile 15 ml centrifuge tube and incubated at 30°C with 
shaking for 8 h. Then, 5 µI of the culture was transferred to a 250 ml flask 
containing 50 ml of YPDA. The culture was incubated at 30°C with shaking at 
250 rpm for 16-20 h until the absorbance at 600 nm reached 0.15-0.3. Then, 
cells were centrifuged at 700 x g for 5 min at room temperature. The supernatant 
was discarded and the cell pellet was resuspended in 100 ml of YPDA. The 
resuspended cells were incubated at 30°C with shaking for 3-5 h until the 
absorbance at 600 nm reached 0.4-0.5. Cells were then centrifuged as above 
and the cell pellet was resuspended in 60 ml of sterile, deionized water. The 
resuspended cells were centrifuged again and the cell pellet was resuspended in 
3 ml of 1.1 x TE/LiAc solution. Cells were separated into two 1.5 ml tubes. Each 
tube was centrifuged at high speed for 15 sec and each pellet was resuspended 
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in 600 µI 1.1 x TE/LiAc. The competent cells were used for transformation 
immediately following preparation. 
2.4.c. Screening by pair-wise yeast cotransformation 
SD/-Leu/-Trp plates: 
46.7 g Minimal SD agar base (Clontech) 
0.64 g -Leu/-Trp DO supplement (Clontech) 
Add water up to 1 liter, autoclave, and pour into plates. 
SD/-His/-Leu/-Trp (TDO) plates: 
46 . 7 g Minimal SD agar base (Clontech) 
0.62 g -His/-Leu/-Trp DO supplement (Clontech) 
Add water up to 1 liter, adjust pH to 5.8, autoclave, and pour into plates. 
SD/-Ade/-His/-Leu/-Trp (QDO) plate: 
46. 7 g Minimal SD. agar base (Clontech) 
0.60 g -Ade/-His/-Leu/-Trp DO supplement (Clontech) 
Add water up to 1 liter, autoclave, and pour into plates. 
Yeast two-hybrid screens were performed to localize the MUC1 binding 
site on the MUC5B polypeptide. MUC 1 bait and MUC5B prey constructs were 
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transformed into yeast cells in pair-wise combinations. In each sterile 1.5 ml tube, 
1 µg DNA-BO bait vector construct (pGBKT7-MUC1 N-terminal), 1 µg AD prey 
vector construct (one of the pGADT7-MUC5B domains) and 0.1 mg herring 
testes carrier DNA (denatured) were mixed. Then, 0.1 ml of yeast competent 
cells was added into the tube and the solution was mixed by vortexing. After 
that, 0.6 ml fresh PEG/LiAc solution was added. The mixture was vortexed at 
high speed and incubated at 30°C for 30 min with shaking at 200 rpm. Next, 70 µI 
of DMSO (Fisher Scientific) was added and mixed by gentle inversion. The 
mixture was heat shocked for 15 min in a 42°C water bath and chilled on ice for 2 
min. The yeast cells were centrifuged at 14,000 rpm for 5 sec and the 
supernatant was removed. The cell pellet was resuspended in 0.5 ml YPD Plus 
liquid medium (Clontech) and incubated at 30°C for 90 min with shaking at 200 
rpm. After recovery, the yeast cells were centrifuged again at 14,000 rpm for 5 
sec and the cell pellet was resuspended in 0.5 ml 1 x TE buffer. An aliquot (100 
µI) of the resuspension was spread onto 100 mm selective SD/-Leu/-T rp plates 
for cotransformation efficiency controls. Another 200 µI of the resuspension was 
spread on each of several 100 mm selective SO/-His/-Leu/-Trp (TOO) plates. The 
plates were incubated upside-down at 30°C until colonies appeared in 
approximately 5 days. C_olonies were replicated from SD/-His/-Leu/-Trp plates to 
SO/-Ade/-His/-Leu/-Trp (QDO)/X-a-Gal plates and incubated under the same 
conditions as described above (each 100 mm QDO plate was plated with 100 µI 
of X-a-Gal [4 mg/ml in dimethylformamide] before use). 
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Positive and negative controls were performed by cotransformation of 
pGBKT7-53 or pGBKT7-Lam (Clontech) with pGADT7 (Clontech) into the yeast 
competent cells. 
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Part 3. MUC1 forms heterotypic protein complexes with other salivary 
proteins 
3.1. Construction of DNA-8D fusions in yeast strain Y187 
3.1.a. Construction of DNA-BD fusions 
One construct encoding the N-terminal 107 residues of MUC 1 was 
prepared in the yeast binding domain (BO) bait vector pGBKT7 (pGBKT7-M1-I) 
as described above. Another construct encoding 191 amino acids (residue 184-
37 4) from the MUC 1 C-terminal domain was prepared in the same vector 
(pGBKT7-M1-II). The latter construct encodes a sparsely glycosylated domain in 
the extracellular region of MUC1 which is connected directly with the 
transmembrane domain . The position of 1-11 in the MUC1 polypeptide backbone 
is indicated in Figure 1. The M1-II DNA fragment was amplified from 
submandibular cDNA as described above using sense and anti-sense primers 
containing Nde1 and Barn H1 restriction sites (italics), respectively . The 
sequences of these primers were : 
M 1-II sense: 
M1-II antisense: 
5' GGACATATGGCATCAGGCTCAGCTTCTAC 3' 
5' AATGGATCCCCCAGCCCCAGACTGGGCAG 3' 
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The amplified M1-II fragment and the pGBKT7 vector were digested with Nde1 
and BamH1 enzymes and ligated to reconstitute the circular pGBKT7-M1-II 
plasmid. 
3.1.b. Transformation of yeast strain Y187 with bait constructs (pGBKT7-
M1-I and pGBKT7-M1-II) 
YPD medium: 
20 g/L Difeo peptone 
10 g/L Yeast extract 
Add water to 950 ml, adjust pH to 5.8, and autoclave 
Cool to 55°C, add 50 ml of sterile 40% glucose (dextrose). 
SD/-Trp plates: 
46. 7 g Minimal SD agar base (Clontech) 
0.74 g -Trp DO supplement (Clontech) 
Add water up to 1 liter, adjust pH to 5.8, autoclave, and pour into plates. 
A small portion of frozen yeast stock Y187 (Clontech) was streaked on a 
YPD plate and the plate was incubated at 30°C for about 3 days until colonies 
appeared. One colony approximately 2-3 mm in diameter was inoculated into 3 
ml of YPD medium in a sterile 15 ml centrifuge tube and the culture was 
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incubated at 30°C with shaking for 8 h. Then, 5 µI of the culture was transferred 
to a 250 ml flask containing 50 ml of YPD. The yeast competent cells were 
prepared as described above. 
Bait constructs pGBKT7-M1-I and pGBKT7-M1-II were separately 
transformed into yeast competent cells using the PEG/LiAc method as described 
above. The cells were plated on SD/-Trp plates to grow for 3-5 days at 30°C until 
colonies appeared. The control construct PGBKT7-53 (Clontech) was also 
transformed into the yeast cells using this method. 
3.1.c. Yeast protein extract: Urea/SOS method 
Cracking buffer stock solution: 
8 M Urea 
5% SOS (w/v) 
40 mM Tris-HCI, pH 6.8 
0.1 mM EDTA 
0.4 mg/ml Bromophenol blue 
Add deionized water to the final volume. 
Cracking buffer (complete): 
Prepare the needed volume just before use 
10 ml cracking buffer stock solution 
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100 µI B-mercaptoethanol 
1 tablet complete mini protease inhibitor cocktail (Roche, Indianapolis, IN) 
One single isolated colony (1-2 mm in diameter, no older than 4 days) 
from each SD/-Trp selective plate expressing the pGBKT7-M 1-I or pGBKT7-M 1-
II protein was inoculated into 5 ml SD/-Trp medium and the cell clumps were 
dispersed by vortexing . The cells were incubated overnight at 30°_C with shaking 
(220-250 rpm). One colony that expressed pGBKT?-53 was cultured in 5 ml 
SD/-Trp medium and one untransformed yeast colony was cultured in 5 ml YPD 
medium for positive and negative controls, respectively. 
The overnight cultures were vortexed for 1 min to disperse cell clumps. 
The entire overnight culture for each clone was separately inoculated in 50 ml of 
YPD medium and the cultures were incubated at 30°C with shaking (220-250 
rpm) until the absorbance at 600 nm reached 0.4-0.6. This took about 4-8 h. The 
absorbance of a 1 ml sample was multiplied by the culture volume (55 ml) to 
obtain the total number of OD600 units. The cultures were quickly chilled by 
pouring them into prechilled 100 ml centrifuge tubes halfway filled with ice. The 
tubes were immediately placed in a prechilled rotor and centrifuged at 1000 x g 
for 5 min at 4°C. The cell pellet was frozen immediately by placing the tube in 
liquid nitrogen. Cells were stored at -70°C until it was ready to proceed with the 
experiment. 
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Complete cracking buffer was prepared and prewarmed to 60°C. The 
frozen cell pellets were quickly thawed by resuspending each one in the 
prewarmed cracking buffer at a ratio of 100 µI of cracking buffer per 7.5 00 600 
units of cells. The tubes were placed in a 60°C water bath for less than 2 min to 
hasten melting. Each cell suspension was transferred to a 1.5 ml screw-cap 
microcentrifuge tube containing 80 µI of glass beads (425-600 µm; Sigma # G-
8772) per 7.5 00 600 units of cells. Samples were heated at 70°C for 10 min and 
vortexed vigorously for 1 min, followed by centrifugation at 14,000 rpm for 5 min 
at 4°C to pellet debris and unbroken cells. The supernatants were transferred to 
fresh 1.5 ml screw-cap tubes and placed on ice (first supernatants). The tubes 
with the pellet were placed in a 100°C boiling water bath for 3-5 min and vortexed 
vigorously for 1 min. The same centrifugation step was carried out and the 
second supernatants were combined with the corresponding first supernatants. 
Samples were boiled briefly, electrophoresed on a 10% acrylamide SOS gel and 
proteins were transferred to nitrocellulose membrane. 
Western blotting experiment was performed under the conditions 
described above to evaluate levels of protein expression from the yeast 
constructs. The blot was incubated with anti-myc antibody (1 :5000, lnvitrogen, 
Carlsbad, CA, USA) and with the secondary HRP-conjugated goat anti-Mouse 
lgG (1 :5000). lmmunoreactive bands were visualized with enhanced 
chemiluminescence reagent as described above. 
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3.2. Construction of DNA-AD fusion library by recombination-mediated 
cloning in yeast strain AH109 
3.2.a. Synthesis of first-strand cDNA 
Human submandibular gland poly A+ RNA was purchased from Clontech. 
It came from a pool of normal, whole submandibular glands from 43 Caucasians . 
The first-strand cDNA was synthesized using a random adaptor primer as 
follows. In a 0.25 ml microcentrifuge tube, 1 µI poly A+ RNA (1 µg/µI, Clontech), 1 
µI CDS 111/6 primer (Clontech), and 2 µI deionized H2O were combined, incubated 
at 72°C for 2 min and cooled on ice for 2 min. The tubes were spun briefly and 
kept at room temperature, while the following reagents (purchased from Clontech 
if not mentioned specifically) were added: 2 µI 5 x first-strand buffer, 1 µI OTT (20 
mM), 1 µI dNTP mix (10 mM) and 1 µI MMLV reverse transcriptase. The 
reactions were mixed by tapping, briefly spun, and incubated at room 
temperature for 10 min followed by 42°C for 10 min. After the incubation, 1 µI 
SMART Ill oligonucleotide was added in and the mixture was incubated at 42°C 
for 1 h in a hot-lid thermal cycler. The tube was then placed at 75°C for 10 min to 
terminate first-strand synthesis. After cooling to room temperature, 1 µI RNase H 
(2 units) was added and incubation was continued at 37°C for 20 min. The first-
strand cDNA was stored at -20°C. 
SMART Ill oligonucleotide: 
5' AAGCAGTGGTATCAACGCAGAGTGGCCATTATGGCCGGG 3' 
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CDS 111/6 primer: (N=A, G, C, or T) 
5' ATTCTAGAGGGCCGAGGCGGCCGACATGNNNNNN 3' 
3.2.b. Amplification of ds cDNA by long distance-PCR (LD PCR) 
Two 100 µI PCR reactions were set up. In each reaction tube, the following 
components (purchased from Clontech if not mentioned specifically) were 
combined: 2 µI first-strand cDNA, 70 µI deionized H20, 10 µI 10 x Advantage 2 
PCR buffer, 2 µI 50 x dNTP mix, 2 µI 5' (sense) PCR primer, 2 µI 3' (anti-sense) 
PCR primer, 10 µI 10 x GC-melt solution, 2 µI 50 x Advantage 2 polymerase mix. 
They were mixed gently by flicking the tube and briefly centrifuged. The ss cDNA 
template contained a sequence complementary to the SMART Ill oligo at the 5' 
end and to the CDS 111 oligo at the 3' end. The sence and anti-sense PCR 
primers contained the SMART Ill and CDS Ill anchor respectively, which served 
as priming sites in the following amplification by long distance PCR. 
5' PCR primer: 5' TTCCACCCAAGCAGTGGTATCAACGCAGAGTGG 3' 
3' PCR primer: 5' GTATCGATGCCCACCCTCTAGAGGGCCGAGGCGG 
CCGACA 3' 
The PCR was carried out using the following program in a hot-lid thermal cycler: 
• 95°C, 30 sec, 
• 20 x cycles : 
95°C, 10 sec 
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68°C, 6 min; increase 5 sec with each successive cycle 
• 68°C, 5 min 
When the cycling was complete, an aliquot (7 ul) of the PCR product from each 
sample was electrophoresed on a 1.2% agarose gel. The gel was examined 
under UV light to verify that sufficient amounts of double stranded cDNA had 
been synthesized. 
3.2.c. Purification of double stranded cDNA with the CHROMA SPIN+TE 400 
Column 
The CHROMA SPIN+ TE 400 Column (Clontech) was used to select for 
cDNA molecules >200 bp. According to the CHROMA SPIN Columns User 
Manual (PT 1300-1 ), the columns were first inverted to resuspend the gel matrix. 
One column was used for each cDNA sample. The column was held upright and 
the break-away end was snapped off. The end of the column was put into a 2 ml 
microcentrifuge collection tube and the top cap was lifted off. The column was 
centrifuged at 700 x g for 5 min to purge the equilibration buffer and re-establish 
the matrix bed. The equilibration buffer and the collection tube were discarded. 
The spin column was put into a second 2 ml microcentrifuge collection tube. The 
cDNA samples (about 93 µI) were applied to the center of the gel bed's flat 
surface inside the column . The column was centrifuged again at 700 x g for 5 min 
and cDNAs > 200 bp were eluted into the collection tube. Duplicate samples 
were combined in a single tube and cDNA products were ethanol precipitated as 
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follows. Sodium acetate (3M, pH 4.8; 1110th volume) and ice-cold 95% ethanol 
(2.5 volume) were added and the tube was mixed by rocking back and forth. The 
mixture was then incubated at -20°C overnight. After incubation, the tube was 
centrifuged at 14,000 rpm for 20 min at room temperature. The supernatant was 
carefully removed with a pipette. The tube was briefly centrifuged at 14,000 rpm 
to bring all remaining liquid to the bottom and all the liquid was carefully 
removed. The pellet was air dried for 10 min and resuspended in 20 µI deionized 
H20. The cDNA was then ready for in vivo recombination with the pGADT7-Rec 
vector. 
3.2.d. Transformation of yeast strain AH109 with ds cDNA and pGADT7-
Rec 
Freezing Medium: 
YPD medium with 25% (v/v) glycerol 
SDI-Leu plate: 
46. 7 g Minimal SD agar base (Clontech) 
0.69 g -Leu DO supplement (Clontech) 
Add water up to 1 liter, autoclave, and pour into plates 
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Competent yeast cells from strain AH 109 was prepared as described above. 
In a sterile, prechilled 15 ml tube, the following components were combined: 
• 20 µI ds cDNA 
• 6 µI pGADT7-Rec (0.5 µg/µI) 
• 20 µI Herring Testes Carrier DNA (denatured by boiling at 100°C for 5 min, 
chilled on ice and repeat once) 
• 600 µI competent yeast cells 
These components were mixed gently by vortexing and 2.5 ml PEG/LiAc 
solution was add in the tube. The tube was gently vortexed again and incubated 
at 30°C for 45 min. Cells were mixed every 15 min during the incubation. After 
incubation, 160 µI DMSO was added to the tube and the solution was gently 
mixed. The tube was then placed in a 42°C water bath for 20 min. Cells were 
mixed every 10 min. Next, cells were centrifuged at 700 x g for 5 min. The 
supernatant was discarded and the pellet was resuspended in 3 ml of YPD Plus 
Liquid Medium (Clontech). The resuspension was incubated at 30°C with shaking 
at 200 rpm for 90 min and centrifuged again as above. The cell pellet was 
resuspended in 10 ml of NaCl Solution (0.9%). Aliquots (200 µI) of this solution 
were spread on each 150 mm SD/-Leu plate. A total of 50 plates were incubated 
at 30°C for 3-6 days until colonies appeared. 
To harvest the transformants, all of the plates were chilled at 4°C for 3-4 h. A 
5 ml aliquot of freezing medium was added to each plate and colonies were 
carefully scraped into the liquid using a bent, sterile Pasteur pipette. All liquids 
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were combined into a sterile flask and mixed well. Cell density was checked 
using a hemocytometer to make sure it was ~2 x 107 cells/ml. The cells 
containing the cDNA library were stored at -80°C in 1 ml aliquots . The pGADT7-
Rec vector was a Sma I-linearized vector with the termini homologous to SMART 
Ill and CDS Ill primers used in the cDNA synthesis. The vector carried the LEU2 
nutritional marker for selection in yeast. Yeast enzymes recombined the ds cDNA 
with pGADT7-Rec, restoring the circular topology of the vector. Transformants 
containing rrcombinant plasmids were selected on SD/-Leu medium. 
3.3. Screening the salivary protein library by cotransformation 
To screen for putative salivary proteins which can interact with MUC1, we 
first cotransformed yeast strain AH 109 with ds cDNA, pGADT7-Rec, and 
pGBKT7-M 1-1. 
Yeast competent cells were prepared as described above. In a sterile 15 
ml tube, the following were combined: 
• 20 µI ds cDNA 
• 6 µI pGADT7-Rec (0.5 µg/µI) 
• 5 µg pGBKT7-M1-I plasmid (1 µg/µI) 
• 20 µI Herring Testes Carrier DNA, denatured 
• 600 µI Yeast Competent cells 
After gentle mixing, PEG/LiAc solution (2.5 ml) was added and mixed again. The 
mixture was incubated at 30°C for 45 min and the cells were mixed every 15 min 
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during the incubation . Then, 160 µI DMSO was added and the tube was placed 
in a 42°C water bath for 20 min. Cells were mixed every 10 min. After the heat 
shock, the cells were centrifuged at 700 x g for 5 min and resuspended in 3 ml 
YPD Plus Liquid Medium (Clontech). The resuspension was incubated at 30°C 
for 90 min with shaking and the cells were centrifuged again after this incubation. 
The cell pellet was resuspended in 6 ml of 0.9% NaCl solution and spread on 
QDO plates (250 µl/150 mm plate). The cotransformation mixture was also 
spread on SD/-Leu/-Trp plates to check the transformation effiency. 
The controls were set up as described above. The positive control was 
cotransformation of SV40 Large T antigen PCR Fragment (Clontech), pGADT7-
Rec, and pGBKT7-53. The negative control was cotransformation of SV40 Large 
T antigen PCR Fragment (Clontech), pGADT7 -·Rec, and pGBKT7-Lam. The 
SV40 Large T antigen is known to interact with p53, but does not interact with 
lamin. The interaction between the SV40 Large T antigen and p53 in the 
cotransformed yeast cells reconstitutes the GAL4 and the reporter gene is 
expressed so that the cotransformants can grow on the selective medium. 
3.4. Screening the salivary protein library by yeast mating 
The salivary gland cDNA library was also screened with pGBKT7-M1-I 
and pGBKT7-M 1-II separately using the yeast mating protocol. 
One large (2-3mm) Y187 colony containing each of the MUC 1 bait 
constructs from the SD/-Trp plate (from Section 3.1.b) was inoculated in 50 ml of 
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SO/-Trp/Kan (20 µg/ml) liquid medium. It was incubated at 30°C overnight with 
shaking at 270 rpm until the absorbance at 600 nm reached 0.8. Then, cells were 
centrifuged at 600 x g for 5 min and resuspended in 5 ml SD/-Trp liquid medium. 
The cell density was determined using a hemocytometer. 
An aliquot ( 100 µI) of the AH 109 cells (library) containing the salivary 
gland cDNA (from Section 3.2.d) was thawed in a room temperature water bath. 
The AH 109 library culture was combined with the 5 ml Y187 bait culture in a 
sterile 2 L flask. The yeast cells were collected together and swirled gently in 45 
ml 2 x YPDA/Kan (50 µg/ml) medium. The cells were incubated at 30°C for 20 h 
with gentle swirling (50 rpm). After 20 h, a drop of the mating culture was 
examined using a Nikon microscope (Nikon TMS) and the zygotes were 
observed under 20X magnification. Mating was continued for four more hours 
and the cells were centrifuged at 1000 x g for 10 min. The cell pellet was 
resuspended in 10 ml 0.5 x YPDA/Kan (50 µg/ml) medium. An aliquot of the 
mating culture (50 µI) was spread on 100 mm SD/-Leu/-Trp plates to check the 
mating efficiency and the rest was spread on QDO plates (200 µI cells/150 mm 
plate). The plates were incubated at 30°C for 5-7 days. The colonies on the QDO 
plates, which grew to >2 mm were streaked out on a fresh SD/-Ade/-His/-Leu/-
Trp/X-a-gal (QDO/X-a-gal) master plate and grown for 4 days at 30°C until 
colonies were at least 1 mm in diameter. 
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The circular pGADT7-T plasmid was used in the controls. The yeast Y187 
cells containing pGBKT?-53 or pGBKT7-Lam were mated with yeast AH 109 cells 
containing the pGADT7-T as positive and negative control, respectively. 
3.5. Analysis of putative positive interactions 
3.5.a. Isolation and purification of plasmid DNA from yeast 
Plasmid DNA from yeast colonies containing putative interacting bait and 
prey constructs was isolated using Zymoprep™ Yeast Plasmid Minipreparation 
Kit (Zymo Reasearch, Orange, CA). Yeast colonies from the QDO plates above 
were picked up and inoculated separately in 1 ml QDO medium in a 15 ml tube. 
They were incubated overnight at 30°C with shaking (250 rpm) until the cells 
were full-grown. Cells were transferred into 1.5 ml microcentrifuge tubes and 
centrifuged at 600 x g for 2 min and the supernatant was discarded. To each 
pellet, 150 µI Solution 1 (Digestion Buffer) and 2 µI of Zymolyase TM were added 
and the pellet was resuspended by vortexing. The resuspended cells were 
incubated at 37°C for 1 h and 150 µI Solution 2 (Lysis Buffer) was added and 
mixed well . Another 150 µI Solution 3 (Neutralizing Buffer) was also added and 
mixed well. The mixture was centrifuged at maximum speed (14,000 rpm) for 2 
min. The supernatant was transferred to a new 1.5 ml tube and 400 µI 
isopropanol was added. After thorough mixing, the tube was centrifuged at 
maximum speed (14,000 rpm) for 8 min. The supernatant was aspirated and all 
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residual liquid was removed after a second brief spin. The pellet, containing 
yeast plasmid DNAs, was dissolved in 35 µI TE buffer (pH 8.0). 
An aliquot of 5 µI of plasmid DNA was used to transform E. coli strain JM 
109 as described above. The transformation reaction was split in half and plated 
equally on LBA and LBK plates. The plates were incubated overnight at 37°C. 
The colonies that grew on LBA plates contained the prey vector (cDNA inserts) 
and the colonies that grew on LBK plates contained the bait vector. 
Colonies containing submandibular gland cDNA library inserts from the 
LBA plates were identified by colony PCR using T7 forward and pGADT7 reverse 
primers (35 cycles of 30 sec at 95°C, 45 sec at 50°C, 60 sec at 72°C). In some 
cases, the yeast plasmid was used as the template for the PCR without first 
transforming the plasmid into bacteria. 
The PCR products were recovered from 1 % agarose gel using the 
QIAquick Gel Extraction Kit (Qiagen) and sequenced at the Genetics Core at 
Boston University Medical Center. 
3.5.b. Confirmation of MUC1-MUC7 interaction by yeast co-transformation 
and Far Western Blotting 
5 x Native Purification Buffer (lnvitrogen): 
250 mM NaH2PO4 
2.5 M NaCl 
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Native Binding Buffer (100 ml): 
80 ml H2O 
20 ml 5 x Native Purification Buffer (lnvitrogen) 
Adjust pH to 8.0 
Native Wash Buffer (50 ml) with 20 mM imidazole: 
50 ml 1 x Native Purification Buffer 
335 µI 3 M lmidazole 
Adjust pH to 8.0 
Native Elution Buffer (15 ml) with 250 mM imidazole: 
13.75 ml 1 x Native Purification Buffer 
1.25 ml 3M lmidazole 
Adjust pH to 8.0 
The putative interaction between MUC 1 and MUC7 was retested in yeast 
by cotransformation. Yeast competent cells were prepared as described above. 
The DNA-BO/bait plasmid (1 µg pGBKT7-M1-I) and one selected AD/library 
plasmid (1 µg pGADT7-MUC7) were cotransformed into AH109 yeast cells and 
plated on TOO plates. The plates were incubated at 30°C until colonies 
appeared. The colonies were then replicated onto the QDO/X-a-gal plates and 
were incubated at 30°C. 
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A stock of E. coli BL21 DE(3) cells expressing a recombinant MUC7 
protein was kindly provided by Dr. Troxler. Briefly speaking, sequences encoding 
the N-terminal domain of MUC7 (residue 1-144) were ligated into the His-tagged 
expression vector pET23b(+) (Novagen). The plasmid rNMUC7was transformed 
into E. coli BL21 DE(3) cells. A small portion of frozen cells was streaked on an 
LBA plate and incubated overnight at 37°C. One colony from the plate was 
inoculated in 5 ml of LBA broth and grown overnight at 37°C with shaking (250 
rpm). The next day, 5 ml of the overnight culture was inoculated into 500 ml of 
'resh LBA broth and the culture was incubated a further 2.5 h until the 
3bsorbance at 600 nm reached 0.8. Protein induction was started by adding 5 ml 
100 mM IPTG to a final concentration of 1 mM. The culture was grown for 
mother 1 h under the same conditions before the cells were spun at 3,000 x g for 
5 min. The cell pellet was saved for protein purification. 
The His-tagged recombinant protein was purified according to the 
=>roBond Purification System (lnvitrogen). To prepare a Probond column, the 
:>robond™ resin (lnvitrogen) was resuspended in its bottle by inverting 
-epeatedly and 2 ml of the resin was transferred into a 10 ml Purification Column 
lnvitrogen). The resin was settled completely by gravity for 10 min and the 
;upernatant was gently aspirated. The column was washed with 6 ml sterile, 
listilled water by inverting several times. The resin was again settled by gravity 
,s described above. For purification under native conditions, 6 ml of Native 
Jinding Buffer was added into the column and mixed with the resin. The resin 
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was re-settled and this procedure was repeated once . The column was then 
ready to use. 
The cell pellet from above was resuspended in 8 ml of Native Binding 
Buffer. Lysozyme (8 mg) was added and the resuspension was incubated on ice 
for 30 min. The cell suspension was sonicated as described above and the 
bacterial cell lysate was centrifuged at 3,000 x g for 15 min. The supernatant was 
transferred to the prepared Purification Column. The binding reaction was 
processed at room temperature for 60 min with gentle agitation of the column on 
a rocker. The resin was re-settled by gravity and the supernatant was aspirated. 
The resin was washed 4 times, each time with 8 ml Native Wash Buffer. After the 
final wash, the cap on the lower end of the column was snapped off and the 
protein was eluted with 8 ml of Native Elution Buffer. The elution was collected in 
1 ml fractions and each fraction was analyzed by SOS-PAGE. The fractions 
containing the recombinant rNMUC7 protein were combined, dialyzed and 
lyophilized. The lyophilized protein was dissolved in 300 µI water and the protein 
concentration was measured by BCA assay. 
Far Western Blotting was carried out as described above. Blots containing 
0.5 µg GST-MUC1 and 0.5 µg GST recombinant proteins were incubated with 
recombinant rNMUC7 (1.5 ug) and probed with a rabbit polyclonal antibody 
against MUC7 (1 :2000). 
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Results 
Part 1. Expression of membrane bound mucin MUC1 in oral epithelial cells 
1.1. MUC1 expression at the transcript level 
As a first step to characterize the expression of the membrane bound mucin 
MUC 1 in oral epithelial cells, reverse transcriptase-polymerase chain reaction 
(RT-PCR) was carried out with RNA isolated from BECs obtained from 6 healthy 
volunteers. Analysis of the PCR products on 1 % agarose gels revealed a 207 bp 
band, consistent with the expected size of the MUC1 amplicon (Figure 5, lane 2). 
Sequence analysis of the PCR product confirmed that it represented a MUC 1 
DNA fragment (data not shown). 
1.2. MUC1 expression at the protein level detected by Western Blotting 
In order to determine if MUC1 protein was also expressed, Western blots 
containing proteins from both the supernatant (soluble proteins) and cell pellet 
(membrane proteins) from BEC lysates were probed with a monoclonal antibody 
that recognizes a peptide sequence in the cytoplasmic tail of MUC1. Equal 
amounts of protein from each sample were electrophoresed on 10% Tricine SOS 
gel and transferred to nitrocellulose membrane. A series of immunoreactive 
bands with molecular weights ranging from 15 to 25 kDa were detected (Figure 
6, lane 3, 4 ). A similar pattern of bands was observed in a lysate from KB cells 
known to constitutively express MUC 1 (Figure 6, lane 2). However, no 
immunoreactive bands were detected in lysates of COS-7 cells, a fibroblastic cell 
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line that does not express MUC 1 (Figure 6, lane 1 ). Bands may represent 
different glycoforms of the MUC1 C-terminal subunit or variously fragmented 
species either produced by the cells or derived during the preparation of cell 
lysates. 
It should be noted that when proteins from cell lysates were boiled in 
sample buffer, the two MUC1 subunits dissociate into the large extracellular 
subunit containing the tandem repeats with a molecular weight of approximately 
250-400 kDa, and the small membrane spanning subunit containing the 
cytoplasmic tail with a molecular weight of approximately 25 kDa. Thus, the CT-2 
monoclonal antibody which is directed against the cytoplasmic domain of MUC 1, 
would identify only the small subunit of MUC1 on Western Blotting. 
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. Figure 5: Expression of MUC1 mRNA transcript in BECs 
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Figure 5: Expression of MUC1 mRNA transcript in BECs. RNA was isolated 
from BECs and reverse transcriptase-polymerase chain reaction (RT-PCR) was 
carried out with intron-spanning MUC 1 specific primers. The amplified DNA 
fragments were checked on a 1 % agarose gel. A band at the size of 207 bp was 
obseNed, which was consistent with the size of the MUC1 amplicon. Lane 1, 1 
kb ladder; lane 2, RT-PCR reaction using MUC1 specific primers. The sizes of 
selected markers in the 1 kb ladder are indicated with arrows. 
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Figure 6: Expression of MUC1 protein in BECs 
25 kDa ---- • 
15 kDa ---- • 
1 2 3 4 
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Figure 6: Expression of MUC1 protein in BECs. BECs were lysed in RIPA 
buffer and proteins in the supernatant (lane 3) and cell pellet (lane 4) were 
electrophoresed on 10% Tris-tricine gels and transferred to nitrocellulose 
membrane. Blots were probed with hamster monoclonal antibody MUC1 CT2 to 
detect the cytoplasmic domain of MUC1. Proteins in cell lysates from KB (lane 2) 
and COS-7 cells (lane 1) were electrophoresed and used as positive and 
negative controls, respectively. The positions of 25 kDa and 15 kDa MUC1 
species are indicated with arrows. 
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1.3. MUC1 expression at the protein level detected by IHC 
To confirm MUC1 protein expression in normal BEC, IHC was performed 
on both buccal smears and on buccal tissue specimens . In these studies, a 
monoclonal antibody directed against an epitope in the TR domain of MUC 1 
(E29) was used. Since the TR sequence occurs up to 100 times in each MUC1 
protein molecule, use of this antibody served to amplify the signal obtained by 
IHC. 
In the experiment using buccal smears, immunoreactivity was found in 
some but not all of the epithelial cells (Figure 7, Panel A). Cells staining 
positively for MUC1 exhibited both cytoplasmic granular and membranous 
staining patterns. The membranous staining was not evenly distributed around 
the cell but focally on one side of the membrane as detected under the light 
microscope. No immunoreactive material was detected in preparations of buccal 
smears in which the primary antibody was omitted (Figure 7, Panel B). 
IHC of fixed buccal tissue specimens showed different staining patterns in 
cells of different epithelial layers (Figure 8, Panel A). Cells of prickle layers 
demonstrated strong membranous and cytoplasmic staining . Cells of 
intermediate layers were mainly membranous focally stained. The membranous 
focal staining was dominantly localized on the side facing the oral cavity. 
lmmunoreactivity on the other side of the membrane, facing the connective 
tissue, was weak or non-detectable, especially in cells in layers close to the oral 
cavity. MUC1 was not detected in either the basal layer or the superficial layer. 
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In all, the normal buccal epithelium showed supra-nuclear distribution of MUC1 
antigen and exhibited staining polarity on the cell membrane. No immunostaining 
was detected when the primary antibody was omitted (Figure 8, Panel B). 
The ductal epithelial cells of the underlying minor salivary glands were 
also strongly stained while no connective tissues were stained positively with the 
MUC 1 antibody (Figure 9, Panel A). This is consistent with recent results from 
our laboratory demonstrating MUC 1 expression in ductal epithelial cells in major 
salivary glands (Liu et al, 2002). In the gingival epithelial tissue obtained from 
periodontal surgery, staining was stronger in all cell layers than in the normal 
buccal epithelium. The positive cells were stained strongly with both cytoplasmic 
granular and membranous staining. Polarity of the membranous staining was 
also observed (Figure 10), similar to that seen in normal buccal epithelial tissue. 
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Figure 7: Analysis of MUC1 protein in cells of buccal smears by IHC 
A: 
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Figure 7: Analysis of MUC1 protein in cells of buccal smears by IHC. A: 
Buccal smears were applied to glass slides, fixed in acetone and processed as 
described in the text. Slides were incubated with MUC1 antibody E29 (1 :50) 
followed by universal secondary antibody and color development with DAB. 
Slides were counterstained with hematoxylin and examined by light microscopy. 
8. Identical buccal smears were treated as in Panel A except that the primary 
antibody was omitted. Magnification in both panels: 200X. 
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Figure 8: Analysis of MUC1 protein in buccal tissue specimen by IHC 
A: 
B: 
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Figure 8: Analysis of MUC1 protein in buccal tissue specimen by IHC. A: 
Normal buccal tissue specimens were sectioned and sections were 
deparaffinized, rehydrated and processed for antigen retrieval. After blocking 
endogenous peroxidase activity, sections were incubated with MUC1 antibody 
E29 (1 :50) and color development was carried out as described in the legend to 
Figure 7. After counterstaining with hematoxylin, slides were examined by light 
microscopy . 8. Sections of buccal mucosal were processed as in Panel A except 
primary antibody was omitted. Magnification in both panels: 1 00X. 
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Figure 9: Detection of MUC1 protein in minor salivary gland in buccal 
specimen by IHC 
A: 
B: 
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Figure 9: Detection of MUC1 protein in buccal mucosal minor salivary 
glands by IHC. A and 8: Different fields in the tissue specimens shown in 
Figures 8A and 88 were examined at higher magnification to visualize minor 
salivary glands in the underlying cell layers. Magnification: 400X. 
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Figure 10: Analysis of MUC1 expression in inflamed gingival epithelium by 
IHC. 
A: 
B: 
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Figure 10: Analysis of MUC1 expression in inflamed gingival epithelium by 
IHC. Gingival tissue was obtained during periodontal surgery from an adult 
patient with severe periodontitis. A., The tissue was sectioned, processed and 
stained with MUC 1 antibody E29 as desribed in the legends to Figures 7 and 8. 
8., Parallel sections in which primary antibody was omitted. Magnification in both 
panels was 100X. 
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Part 2. Protein-protein interaction between MUC1 and MUC5B 
2.1. Construction and expression of GST-M1 
2.1.a. Construction of MUC1 expression plasmid 
A schematic diagram of the structural organization of MUC1 is presented 
in Figure 11A. The two horizontal arrows indicate the positions of 5' (sense) and 
3' (antisense) primers used to amplify a DNA fragment encoding the 107 N-
terminal amino acids of MUC1 which are located upstream of the TR region. The 
physico-chemical parameters of this fragment are displayed in Table 2 A and 8. 
The nucleotide and deduced amino acid sequence of the 321 bp PCR 
product from submandibular gland cDNA encoding the MUC1 apomucin N-
terminal region 107 amino acids are shown in Figure 11 8. This fragment was 
recovered from agarose gels, digested with 8amH1 and Xho1 and cloned into 
the expression vector pGEX-5X-2 at the same restriction enzyme sites. 
Sequencing analysis of the construct verified in frame ligation and the positions 
of the translation start and stop codons are marked with arrows (Figure 12). 
2.1.b. Expression of recombinant N-terminal apomucin of MUC1 
The MUC1 construct (pGEX-M1) was transformed into 8L21 DE(3) cells to 
express the recombinant GST-M1 protein. Pilot experiments conducted to 
determine conditions for optimal expression showed that adequate protein was 
obtained when mid-log phase cells were induced for 2 h at 30°C with 1 mM IPTG 
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and rotary shaking at 200 rpm. A control induction experiment was carried out in 
the same manner using BL21 DE(3) cells transformed with empty pGEX-5X-2 
vector to generate GST control protein. An aliquot (1 ml) of cell culture was taken 
out before and after IPTG induction and centrifuged. The proteins in the cell 
pellet were examined by SOS-PAGE and stained with Coomassie Brilliant Blue 
R-250 (Figure 13). Expression of the GST-M 1 fusion protein resulted in 
increased synthesis of a protein with an apparent molecular weight of 42 kDa 
after induction with IPTG (Figure 13, lane 2). Expression of the empty pGEX-5X-
2 vector resulted in the synthesis of a 27 kDa protein after IPTG induction (Figure 
13, lane 4). In both cases, the intensity of the protein bands was much greater 
after IPTG induction (Figure 13, lanes 2 and 4) than before (Figure 13, lanes 1 
and 3). 
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Figure 11: Location, nucleotide sequences and deduced amino acid 
sequences of the MUC1 N-terminal domain I 
A: 
B: 
NH2 I.__ __ ~------~---~ COOH 
I 
107 aa 
TR 
420-2500 aa 
II TM CT 
227 aa 27 aa 69 aa 
aca ggt tct ggt cat gca age tct ace cca ggt gga gaa aag gag 
TGSGHASSTPGGEKE 
act tcg get ace cag aga agt tea gtg ccc age tct act gag aag aat get gtg agt atg 
TSATORSSV PS STE KNAVSH 
ace age age gta etc tee age cac age ccc ggt tea ggc tee tee ace act cag gga cag 
TSSVLSSHS PGSGSSTTQGQ 
gat gtc act ctg gee ccg gee acg gaa cca get tea ggt tea get gee ace tgg gga cag 
DVTLAPAT E PASGSAATVGQ 
gat gtc ace tcg gtc cca gtc ace agg cca gee ctg ggc tee ace ace ccg cca gee cac 
DVTSVPVTRPALGSTT PPAH 
gat gtc ace tea gee ccg gac aac aag cca gee ccg 
DVTS AP DNK PAP 
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Figure 11: Location, nucleotide and deduced amino acid sequence of the 
MUC1 N-terminal domain I. A., Schematic diagram of the structural 
organization of MUC1. The arrows indicate the positions of 5' and 3' primers 
used to amplify N-terminal domain I. B., The nucleotide and deduced amino 
acids of MUC1 N-terminal domain I. 
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Table 2: The physico-chemical parameters of the MUC1 N-terminal domain I 
A: Amino acid composition 
Amino Acid Composition Percentage 
Ala (A) 12 11.2% 
Arg (R) 2 1.9% 
Asn (N) 2 1.9% 
Asp (D) 4 3.7% 
Cys (C) 0 0.0% 
Gin (Q) 4 3.7% 
Glu (E) 4 3.7% 
Gly (G) 10 9.3% 
His (H) 3 2.8% 
lie (I) 0 0.0% 
Leu (L) 3 2.8% 
Lys (K) 3 2.8% 
Met (M) 1 0.9% 
Phe (F) 0 0.0% 
Pro (P) 12 11.2% 
Ser (S) 22 20.6% 
Thr (T) 16 15.0% 
Trp 0/V) 1 0.9% 
Tyr (Y) 0 0.0% 
Val (V) 8 7.5% 
B: Biochemical properties 
Number of amino acids 107 
Molecular weight 10416.0 
Theoretical pl 5.37 
Total negatively charged residues 8 
Total positively charged residues 5 
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Figure 12: Structure of expression vector pGEX-5X-2 
lac Iq 
MUC I N-terminal insert 
Stop codon 
pGEX-SX-2 
4973bp 
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Figure 12: Structure of expression vector pGEX-5X-2. The 321 bp DNA 
fragment encoding MUC1 N-terminal region was cloned into the expression 
vector pGEX-5X-2. The recombinant protein contained a 27 kDa glutathione S-
transferase (GST) fusion protein. The arrows indicate the positions of the start 
and stop codons. 
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2.1.c. Purification of recombinant protein GST-M1 by affinity 
chromatography 
Based on results of the small scale pilot experiments, two 500 ml cultures 
of 2 x YT-G/ampicillin medium were inoculated with cells containing the pGEX-
M 1 plasmid. Cells were induced with IPTG and the recombinant protein GST-M1 
was isolated by affinity chromatography. Fractions from the GSTrap TM column 
containing the highest amounts of protein were dialyzed and lyophilized. The 
protein was then dissolved in water and the concentration was measured using 
the BCA protein assay. The quantity of purified GST-M1 from 1 liter of culture 
medium was around 1 mg. The control GST protein was purified by the same 
method. To assess purity of the recovered proteins, equal amounts of GST-M1 
and GST protein samples were electrophoresed, and gels were either stained 
with Coomassie blue (Figure 14A) or blotted onto nitrocellulose membrane. Blots 
were probed with a monoclonal antibody against GST (Figure 14B). Panel A 
shows the Coomassie blue stained gel containing purified GST (lane 1) and 
GST-M1 (lane 2). On stained gels, a single protein band was detected in lanes 
containing both GST and GST-M 1 (Figure 14A, lane 1 and 2) indicating a high 
level of purification was achieved. Similar results were obtained on Western Blots 
of identical samples probed with anti-GST (Figure 14B, lane 1 and 2). As 
expected, purified GST had an apparent molecular weight of 27 kDa while GST-
M1 has an apparent molecular weight of 42 kDa (Figure 14A, B - arrows). 
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Figure 13: Expression of GST-M1 recombinant protein 
GST-M1 GST 
42 kDa _____. 
27 kDa-----. 
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Figure 13: Expression of GST-M11 recombinant protein. An aliquot of 1 ml 
BL21 DE(3) cells expressing GST-M1 recombinant protein was harvested by 
centrifugation before and after IPTG induction. The cell pellets were boiled in 
sample buffer and the extracted proteins were loaded on 12% SOS 
polyacrylamide gels. The gels were stained with Coomassie Brilliant Blue R-250 
after electrophoresis. Cells transformed with the empty pGEX-5X-2 vector were 
treated in the same way. Lane 1: extract of cells expressing GST-M1 before 
IPTG induction, lane 2: extract of cells expressing GST-M1 after IPTG induction, 
lane 3: extract of cells expressing GST before IPTG induction, Lane 4: extract of 
cells expressing GST after IPTG induction. Arrows indicate the positions of 42 
kDa GST-M 1 fusion protein and the 27 kDa GST control protein. 
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Figure 14: Purification of GST-M1 recombinant protein 
A: B: 1 2 
GST GST-M1 Std 
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1 2 
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Figure 14: Purification of GST-M1 recombinant protein. A large scale culture 
of 500 ml BL21 OE(3) cells expressing GST-M1 recombinant protein was 
harvested after IPTG induction. Cell pellets were resuspended in PBS, sonicated 
and centrifuged. The supernanants were pumped through 1 ml GSTrap TM affinity 
columns, washed and eluted. The peak fractions of elution from the GSTrap TM 
column were dialyzed and lyophilized. The purified GST-M1 protein was 
dissolved in water and the concentration was measured by BCA protein assay. 
The GST control protein was purified in the same way. A: Equal amount (2 µg) of 
GST and GST-M 1 were electrophoresed on 12% SOS polyacrylamide gels and 
the gels were stained with Coomassie Brilliant Blue R-250. The arrows indicate 
the positions of the 27 kOa GST protein (lane 1) and 42 kOa GST-M 1 protein 
(lane 2). B: Equal amounts (0.5 µg) of GST and GST-M1 were electrophoresed 
on 12% SOS polyacrylamide gels, blotted and blots were probed with monoclonal 
antibody against GST (1 :5000). The arrows indicate the positions of 
immunoreactive 27 kOa GST (lane 1) and immunoreactive 42 kOa GST-M1 (lane 
2), consistent with the results of Coomassie Brilliant Blue staining. 
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2.2. GST pull down assay of MUC1 and MUC5B 
To determine if the N-terminal fragment of MUC1 could form a complex 
with the gel-forming mucin, MUC5B, equal amounts of GST-M1 and GST control 
protein were incubated with purified MG1 (MUC58) in simulated saliva buffer in 
two separate 1.5 ml microcentrifuge tubes. The mucin complexes were isolated 
using GST beads. After thorough washing with PBST, complexed proteins were 
dissociated in gel loading buffer and examined by SOS-PAGE and Western 
blotting. Blots were incubated with a rabbit polyclonal anti-MG1 antibody. 
In control experiments, Western blots of purified MG1 were probed with 
the anti-MG1 antibody. Due to the high molecular weight of native MG1, the 
immunoreactive band was detected in the stacking gel (Figure 15A). 
The results of GST pull down experiments performed with GST-M1/MG1 
and GST/MG1 are shown in Figure 158. An immunoreactive band in the stacking 
gel was observed after incubating MUC5B with GST-M1 (Figure 158, lane 1 ), but 
not with GST alone (Figure 158, lane 2). This provides good evidence for the 
existence of a MUC 1-MUC5B complex. 
116 
Figure 15: GST pull down assay of MUC1 and MUC5B 
A: 
Bottom of____. 
stacking gel 
200 kDa ____. 
MG1 
Western 
Anti-MG1 
B: 
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stacking gel 
200 kDa ____. 
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Figure 15: GST pull down assay of MUC1 and MUCSB. A: Western Blot of 
purified MG1 from human submandibular/sublingual secretion (HSMSL) probed 
with rabbit polyclonal anti-MG1 antibody (1: 1000) and secondary HRP-
conjugated goat anti-rabbit lgG (1 :7500). The positions of the interface between 
stacking and separating gels and the 200 kDa marker are indicated with arrows. 
B: Equal amounts of MG1 were incubated with GST-M1/beads (lane 1) or 
GST/beads (lane 2) and the protein complexes were dissociated in sample 
buffer, electrophoresed on 8% SOS polyacrylamide gels, and blots were probed 
with the same anti-MG1 antibody. Arrows are as described in A. 
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2.3. Far Western Blotting of MUC1 and MUC5B 
To confirm the results obtained in GST pull down experiments, a series of 
Far Western blotting experiments was performed. Equal amounts of GST-M1 and 
GST control protein were electrophoresed on SOS gels and blotted onto 
nitrocellulose membrane. Blots were incubated with purified MG1 in interaction 
buffer overnight at 4°C. After washing, blots were probed with anti-MG1 antibodies 
to identify potential MUC 1-MUC5B interactions. As shown in Figure 16, an 
immunoreactive 42 kDa band corresponding to GST-M1 was detected (Figure 16A, 
lane 1 ), but no immunoreactive 27 kDa band corresponding to GST was observed 
(Figure 16A, lane 2). To verify that equal amounts of GST-M1 and GST were 
electrophoresed, the blot was stripped and re-probed with anti-GST antibodies, 
demonstrating the 42 kDa GST-M 1 and 27 kDa GST bands (Figure 168, lanes 1 
and 2). These results provide further evidence that MUC1 and MUC58 can form a 
complex. 
2.4. Yeast two hybrid screens 
2.4.a. Construction of DNA-BO and DNA-AD fusions 
The next series of experiments was designed to determine which domain 
of the gel-forming mucin, MUC5B, interacted with the N-terminal fragment of 
MUC1. To do this, the MATCHMAKER GAL4 Two-Hybrid System 3 (Clontech) 
was selected for identifying and investigating protein-protein interactions in vivo 
using the yeast two-hybrid assay. 
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The pGBKT7 vector expresses proteins fused to amino acids 1-14 7 of the 
DNA binding domain of the transcription factor GAL4 (GAL4 BO). It carries the 
Kanr for selection in E.coli and the TRP nutritional marker for selection in yeast. It 
also contains a c-myc epitope tag for Western blotting identification. pGBKT7 
replicates autonomously in both E. coli and S. cerevisiae from the pUC and 2 µ 
ori, respectively. A fragment encoding the N-terminal domain of MUC 1 was 
inserted in frame with the 3' end of the GAL4 DNA-BO for expression of fusion 
proteins in yeast (Figure 17). 
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Figure 16: Far Western Blotting of MUC1 and MUC5B 
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Figure 16: Far Western Blotting of MUC1 -and MUC58. A: Equal amounts (6 
µg) of GST-M1 fusion protein and GST control protein were electrophoresed on 
12% SOS gel, transferred to nitrocellulose membrane, incubated with 20 µI 
purified MG1 (1.6 µg), and blots were probed with rabbit polyclonal anti-MG1 
antibody (1 :1000) and the secondary HRP-conjugated goat anti-rabbit lgG 
(1 :7500). The positions of the 42 kDa GST-M1 and the 27 kDa GST proteins are 
indicated. B: The blot in A was stripped and re-probed with anti-GST antibody 
without MG1 incubation. 
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Figure 17: Structure of yeast pGBKT7 vector 
TRP1 
2 µ ori 
bait domain 
pGBKT7 
7.3 kb 
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Figure 17: Structure of yeast pGBKT7 vector. pGBKT7 is the DNA-BO vector 
containing unique restriction sites in frame with the 3' end of the GAL4 DNA-BO 
to construct fusions with a bait protein. The N-terminal 107 residue of MUC1 was 
the bait domain (gray bar) to be fused with the DNA-BO in pGBKT7. The origins 
of replication (PUC, and 2 µ ori), antibiotic resistance gene (Kan) and nutritional 
selection marker (TRP1 gene) are indicated. 
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The pGADT7 vector expresses proteins fused to amino acids 768-881 of 
the activation domain of the transcription factor GAL4 (GAL4-AD) . It carries the 
Ampr for selection in E.coli and the LEU nutritional marker for selection in yeast. 
It also contains an HA epitope tag for Western blotting identification. pGADT7 
replicates autonomously in both E. coli and S. cerevisiae from the pUC and 2 µ 
ori, respectively. Each of a series of MUC58 domains was inserted in frame with 
the 3' end of the GAL4 AD for constructing 5 separate fusion proteins (Figure 
18). The domains examined were the 03 domain from the MUC58 N-terminal 
region (residue 893-1249) and the 04, C1, C2, and CK domains from MUC58 C-
terminal region (residue 292-632, 643-706, 744-808, and 829-983, respectively) . 
2.4.b. Pair-wise yeast co-transformation 
The construct encoding the MUC 1 bait protein was co-transformed into 
yeast strain AH109 with prey constructs encoding the MUC58 03, 04, C1, C2 
and CK domain in 5 separate pair-wise combinations. 
When bait and prey fusion proteins interact in the yeast reporter strain 
AH109 , the GAL4 DNA-BO and AD are brought into proximity and activate 
transcription of four reporter genes (Figure 19), which leads to the growth of 
colonies on selective medium (Table 3). 
The co-transformants were first plated on SD/-Leu/-Trp plates. The TRP1 
nutritional marker from the pGBKT7 vector and the LEU2 nutritional marker from 
the pGADT7 vector allowed those transformants that took both plasmids to grow 
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on the Leu/Trp dropout medium. All five MUC1/MUC58 pairs as well as both the 
positive and negative control transformations yielded approximatelly 80 colonies 
on the SO/-Leu/-Trp plates after 5 days incubation, which showed a high 
transformation efficiency. Equal volumes of transformation reactions were plated 
on the SO/-Leu/-Trp/-His (TOO) plates at the same time. Transformants 
containing two interacting fusion proteins expressed Leu/Trp from the prey/bait 
vectors and His from the activation of the yeast reporter gene so that they could 
grow on TOO plates. Among the five pairs, only the transformants containing 
MUC1 and MUC58-CK, as well as the positive control, grew on the selective 
TOO plates after 5 days incubation as shown in table 4. Five of the twelve 
colonies from MUC 1 /MUC5B-CK TOO plates were replicated on the SO/-Leu/-
Trp/-His/-Ade/X- a-gal (QOO/X-a-gal) plates for more stringent selection. All 
colonies grew and the color changed to blue after 3 days because of the a-
galactosidase activity resulting from activation of the MEL 1 reporter gene. 
These results confirm that MUC 1 and MUC5B can form complexes and 
localize the MUC 1 binding site to the MUC58 CK domain. 
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Figure 18: Structure of yeast vector pGADT7 
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Figure 18: Structure of yeast vector pGADT7. PGADT7 is the AD vector 
containing unique restriction sites in frame with the 3' end of the GAL4 AD to 
construct a fusion protein with a target protein (gray bar). There were five targets 
fused with the AD separately. They were 03, 04, C1, C2, and CK domain of 
MUC5B. The origins of replication (PUC, and 2 µ ori), antibiotic resistance gene 
(Amp) and nutritional selection marker (LEU1 gene) are indicated. 
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Figure 19: Principle of the yeast two hybrid assay 
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Figure 19: Principle of the yeast two hybrid assay. In the pair-wise yeast 
cotransformation, if MUC1/DNA-BD fusion protein interacts with one or more of 
the MUC58/AD fusion proteins, the DNA-BO and AD domains will be brought into 
proximity and activate transcription of the reporter genes, which lead to the 
growth of colonies on selective medium. 
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Table 3: Yeast selective medium a 
Yeast cell SDI-Leu S0/-Trp S0/-Leu/- TOO ODO Q0O/X-a-
Trp gal 
Empty 
- - - - - -
yeast 
Yeast with + - - - - -
bait 
Yeast with 
- + - - - -
prey 
Yeast with + + + - - -
bait & prey 
Yeast with + + + + + + 
interacted 
bait & prey 
a+ indicates growth on selective plates; - indicates no growth. 
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Table 4: Results of MUC1 and MUC58 pair-wise cotransformation a 
MUC5B-D3 MUC5B-D4 MUC5B-C1 MUC5B-C2 MUC5B-Ck 
MUC1-N - - - - + 
a+ indicates growth on selective TOO and QDO/X-a-gal plates; - indicates no growth. 
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Part 3. MUC1 forms heterotypic protein complexes with other salivary 
proteins 
3.1. Construction of MUC1 DNA-8D fusions in yeast strain Y187 
The two MUC1 constructs pGBKT7-MUC1-I and pGBKT7-MUC1-II were 
separately transformed into yeast strain Y187 and plated onto SD/-Trp selective 
plates. Colonies that grew on the plates expressed the recombinant bait proteins 
and were used to inoculate small scale cultures. Proteins were extracted from the 
cultured cells using the Urea/SOS method and checked by SOS-PAGE. Western 
blotting was performed using a monoclonal anti-myc antibody. 
The pGBKT7 vector expresses proteins fused to amino acids 1-14 7 of the 
GAL4 DNA binding domain (DNA-BO). In yeast cells, fusion proteins are 
expressed at high levels from the constitutive ADH 1 promoter (bases 30-736) 
and transcription is terminated by the T7 and ADH 1 transcription termination 
signals (bases 1335-1381 ). pGBKT7 contains unique restriction sites in frame 
with the 3' end of the GAL4 DNA-BO for constructing fusion proteins with a bait 
protein. The bait protein is expressed as a fusion with a c-myc epitope tag, which 
can be identified with the antibodies raised to c-myc. 
In this study, blots containing the pGBKT7-MUC1 fusion proteins I and II 
revealed immunoreactive 35 kDa and 44 kDa bands when probed with anti-myc 
antibody (Figure 20, lanes 1 and 2). 
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Figure 20: Expression of MUC1/DNA-BD fusion proteins in yeast strain 
Y187 
M1-I M1-II 
+-- 44 kDa 
35 kDa • 
2 
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Figure 20: Expression of MUC1/DNA-BD fusion protein in yeast strain Y187. 
Proteins extracted from yeast strain Y187 transformed with pGBDT7-M1-I and 
pGBDT7-M1-II constructs were analyzed by SOS-PAGE on 12% gels. The blot 
was probed with the first anti-myc antibody (1 :5000) and the secondary HRP-
conjugated goat anti-mouse lgG (1 :5000). Lane 1: A band at the size of 35 kDa 
was detected, representing the M1-I/DNA-BD fusion protein ; Lane 2: A band at 
the size of 44 kDa was detected, representing the M1-II/DNA-BD fusion protein. 
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3.2. Construction of DNA-AD fusion library by recombination-mediated 
cloning in yeast strain AH109 
Double stranded cDNA was synthesized from human submandibular 
gland poly A+ RNA: The first-strand cDNA was synthesized using MMLV 
(Moloney Murine Leukemia Virus) Reverse Transcriptase (RT) to transcribe RNA 
into DNA with a random primer CDSlll/6. Transcripts were efficiently copied into 
ds cDNA using CLONTECH's SMART (Switching Mechanism at 5' end of RNA 
Transcript) technology and amplified by Long Distance-PCR. An aliquot (7 µI) of 
the PCR reaction was analyzed on a 1.2% agarose/EtBr gel alongside of a DNA 
size marker and the positive control synthesized using Human Placenta Poly A+ 
RNA provided by Clontech. With both the positive control cDNA (lane 1) and the 
submandibular gland cDNA (lane 2), a smear of EtBr staning was observed, 
indicating synthesis of cDNAs ranging in size from approximately 2kb-0.2 kb 
(Figure 21). Each ds cDNA product was then purified with a CHROMA SPIN+ TE-
400 Column and transformed into yeast strain AH 109 together with the linear 
pGADT7 -Rec vector. 
The pGADT7-Rec vector has all the characteristics that vector pGADT7 
has, plus the capability of engineering and constructing a GAL4 AD/cDNA library 
by homologous recombination in yeast. Yeast enzymes recombine the ds cDNA 
with pGADT7-Rec, restoring the circular topology of the vector (Figure 22). In the 
current study, transformants containing recombinant cDNA library plasmids were 
selected on SDI-Leu plates. 
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Figure 21: Double-stranded cDNA synthesized from human salivary gland 
poly A+ RNA 
2.0 kb_. 
1.0 kb-. 
0.5 kb-. 
0.2 kb-. 
M 1 2 
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Figure 21: Double-stranded cDNA synthesized from human salivary gland 
poly A+ RNA. 1 µg human submandibular gland poly A+ RNA was used as 
template to synthesize first strand cDNA with the random primer CDS 111/6. 
Control reactions were performed with human placenta poly A+ RNA. The LD-
PCR reactions were set up with 2 µI of the single stranded cDNA. Aliquots (7 µI) 
of placenta (lane 1) and submandibular gland (lane 2) ds cDNA PCR products 
were analyzed on a 1.2% agarose/EtBr gel next to a DNA molecular weight size 
marker (M). 
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Figure 22: Structure of yeast vector pGADT7-Rec 
SMART Ill 
Sequence 
GAL4AD 
CDSIII 
primer 
pGADT7-Rec LEU2 
8.0 kb 
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Figure 22: Structure of yeast vector pGADT7-Rec. pGADT7-Rec is a Sma I 
linearized vector. Its termini are homologous to SMART 111 and CDS 111 primers 
used in the cDNA synthesis. In addition to the characteristics of pGADT7 vector, 
pGADT7-Rec can recombine ds cDNA, restoring the circular topology of the 
vector. Yeast enzymes perform this reaction in yeast cells. Transformants 
containing recombinant plasmids can be selected on SD/-Leu medium due to the 
presence of LEU2 nutritional marker. 
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Figure 23: Scheme for construction of GAL4 AD fusion libraries by 
recombination-mediated cloning in yeast 
Submandibular gland poly A+ RNA 
5' poly A 3' 
SMART III IIV I 
Oliqonucleotide 
¢==i CDS Ill random primer 
coupled with (dC) tailing by RT l First strand synthesis 
5' r®l~t1iltl!~f1GGG 
CCC 
~ Poly A 
l Template switching and extension by RT 
5' ~ GGG 
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l Amplification by LD-PCR 
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ds cDNA with SMART 11111vi 
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GAL4 AD Vector assembly 
Figure 23: Scheme for construction of GAL4 AD fusion libraries by 
recombination-mediated cloning in yeast. A GAL4 AD fusion library was 
produced by cotransforming yeast cells with submandibular ds cDNA and Sma I 
linearized pGADT7-Rec. The SMART Ill and CDS Ill sequences, which were 
incorporated into the cDNA by RT and LD-PCR, have been engineered into the 
pGADT7-Rec plasmid. The linear plasmid was restored to the circular form by 
recombination with overlapping sequences at the ends of the cDNA in yeast. 
Positive transformants were selected on SD/-Leu medium. 
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3.3. Screening of the submandibular gland protein library by 
cotransformation 
To screen for proteins which interact with MUC1, we first used the yeast 
cotransformation protocol to transform the ds cDNA, pGADT7-Rec vector and 
pGBKT7-M1-I plasmid into yeast strain AH109. Transformants were plated on 
SD/-Leu/-Trp and QDO plates and plates were incubated for 5 days at 30°C. 
After the incubation, those cells that contained a circular pGADT7 plasmid and 
took up the bait plasmid could express LEU and TRP nutritional markers and 
grew on the SO/-Leu/-Trp plates. Cells containing the interacting bait and prey 
fusion proteins would also activate the reporter genes HIS and ADE so that they 
could grow on the QDO selective plates. There were about 20 colonies on the 
SO/-Leu/-Trp plates for the positive control and none for the negative control. On 
the positive control QDO plate, 15 colonies were observed. For the library 
cotransformation, about 12 colonies grew on the SO/-Leu/-Trp indicating that the 
transformation efficiency was not high. No colonies were observed on the library 
screen QDO plates. 
3.4. Screening the submandibular gland protein library by yeast mating 
Another yeast two hybrid screen protocol, yeast mating, was then used for 
the library screeing. To determine the library size, AH109 library transformants 
harvested from SO/-Leu plates were diluted 106 times. An aliquot (100 µI) of the 
dilution was spread on one SO/-Leu plate. There were about 300 colonies grew 
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on the plate after 3 days incubation. The number of clones in the library was 
calculated as (300 x 1000 µl/ml)/(100 µIx dilution factor10-6) = 3 x 109 /ml. 
Overnight 50 ml cultures of Y187 cells containing M1-I and M1-II baits 
were grown until the 00 600 nm reached 0.8. The cells were condensed into 5 ml 
of SD/-Trp medium by centrifugation and the hemocytometer assay showed that 
the cfu of the bait cells was around 5 x 109 /ml. 
Y187 culture of each bait (5 ml) was combined with 100 µI AH109 library 
culture in 45 ml 2 x YPDA/Kan (50 µg/ml). Cells containing the MUC1 bait and 
the prey library were swirled together at 30°C for 24 h, centrifuged and the cell 
pellet was resuspended in 10 ml of 0.5 x YPDA/Kan (50 µg/ml). The mating 
mixture was spread out on QDO plates at 200 µI cells per 150 mm plate for total 
50 plates . After 5 days of incubation at 30°C, there were 12 colonies from the 
M 1-I/library screen and 58 colonies from the M 1-II/library screen growing on the 
plates. Those colonies were replicated onto a new QDO/X-a-gal master plate 
and incubated at 30°C for another 3 days. They grew to more than 1 mm in 
diameter and turned blue, indicating that they contained putative interacting bait 
and prey proteins. 
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3.5. Analysis and verification of putative positive interactions 
3.5.a. Isolation of plasmid DNA from yeast and identification of the 
corresponding proteins 
Yeast plasmid DNA was isolated using Zymoprep™ Yeast Plasmid 
Minipreparation Kit (Zymo Reasearch). PCR reactions were carried out to amplify 
inserts from the salivary gland library in the prey vector using the T7 forward and 
pGADT7 reverse primers. The PCR products were directly sequenced at the 
Genetics Core at Boston University Medical Center. Sequences were compared 
to those in GenBank using the BLAST program. This analysis revealed a number 
of known salivary proteins as well as several transmembrane proteins. Two 
salivary proteins, MUC7 (Bobek et al., 1993) and basic praline rich protein 3 
(bPRP3) (Lyons et al., 1988), and two immuno-related proteins, M83 (TMEM8) 
(Motohashi et al., 2000) and a protein similar to ICAM-3 (Fawcett et al., 1992) 
were identified as putative MUC1 N-terminal domain I interacting proteins (Table 
5A). The MUC1 C-terminal domain II interacting proteins included the salivary 
proteins parotid secretory protein (PSP) (Madsen and Hjorth, 1985) and bPRP3, 
as well as the transmembrane proteins actin-binding protein 280 (Tigges et al., 
2003) and epithelial cell receptor protein tyrosine kinase (EphA2) (Lindberg and 
Hunter, 1990) (Table 58). 
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3.5.b. Confirmation of MUC1-MUC7 interaction by Far Western Blotting 
Studies were performed to verify the identified interactions between 
MUC1-I and MUC7. This interaction was of particular interest since we had 
shown in Part 2 of this work that MUC 1 formed a complex with the other secreted 
salivary mucin, MUC5B. 
His-tagged recombinant MUC7 protein (rNMUC?) was expressed after 
IPTG induction in bacterial cells and purified by affinity chromatography from cell 
lysates. Equal amounts of GST-M1 and GST control protein (0.5 µg) were 
electrophoresed on SOS-PAGE and blotted onto nitrocellulose membrane. Blots 
were incubated with purified rNMUC7 in interaction buffer overnight at 4°C. After 
washing, blots were probed with anti-MUC7 antibodies to detect MUC1-MUC7 
interactions. An immunoreactive 42 kDa band was detected in lanes containing 
GST-M1 (Figure 24A, lane 1) but an immunoreactive 27 kDa band was not 
detected in lanes containing GST alone (Figure 24A, lane 2). This confirmed the 
results of the two hybrid analysis and indicated that the N-terminal region of 
MUC 1 can form a complex with the N-terminal region of MUC7 in vitro. Equal 
loading of recombinant proteins was confirmed by probing an identical blot with 
anti-GST antibodies (Figure 248). 
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Table 5: Interacting proteins identified by yeast mating 
A: Proteins that have the potential to interact with domain I of MUC 1 
Proteins Number of clones Interaction domain 
MUC7 3 N-terminal + Tandem repeat: residue 72-217 
Basic praline rich proteins 4 Variable basic PRPs 
I-CAM3 similar protein 1 The 4m extracellular lg-like C2-type domain 
M83 (TMEM8) 4 Extracellular : residue 357-450 
B: Proteins that have the potential to interact with domain II of MUC 1 
Proteins Number of clones Interaction domain 
Parotid secreted protein 1 Residue 138-24 7 
Basic praline rich proteins 5 Variable basic PRPs 
Actin binding protein 280 (filamin A, alpha) 1 Residue 1861-1947 
Epithelial cell receptor protein tyrosine kinase 1 Residue 311-410 
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Figure 24: Far Western Blotting of MUC1 and MUC7 
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Figure 24: Far Western Blotting of MUC1 and MUC7. Equal amounts (0.5 µg) 
of GST-M 1 fusion protein (lane 1) and GST control protein (lane 2) were 
electrophoresed on 12% SOS gels and transferred to nitrocellulose membrane. 
A: Blots were incubated with 1.5 µg recombinant MUC7 protein, and probed with 
with rabbit polyclonal anti-MUC7 antibody (1 :2000) and HRP-conjugated goat 
anti-rabbit lgG (1 :7500) . The positions of the 42 kDa GST-M1 and the 27 kDa 
GST proteins are indicated with arrows. 8: A duplicated blot was probed with 
anti-GST antibody without MUC7 incubation. Both the 42 kDa GST-M1 (lane 1) 
and the 27 kDa GST (lane 2) were detected. 
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Discussion 
Part 1. Expression of membrane bound mucin MUC1 in oral epithelial cells 
The oral cavity is lined with both non-keratinized stratified squamous 
epithelium in buccal mucosa, alveolar mucosa and soft palate, and keratinized 
epithelium in gingiva and the hard palate. Accumulating evidence indicates that 
these epithelial layers are not merely mechanical barriers but also contain 
important elements of the innate immune system. Several recent studies have 
shown that cytokine responses of oral epithelial cells after infection were 
correlated with the adhesive/invasive potential of oral pathogens and that lectin-
like interactions were involved in the attachment (Han et al., 2000; Sandros et al., 
2000). 
In the oral cavity, the expression of MUC1 in normal salivary glands, 
premalignant and malignant oral lesions originated from oral epithelial cells has 
been well demonstrated. In this study, we showed for the first time that MUC1 
RNA transcripts and MUC1 proteins were expressed in oral epithelial cells by 
RT-PCR, Western blotting and IHC. In the IHC studies carried out by Nitta et al 
(Nitta et al., 2000) and Sengupta et al (Sengupta et al., 2001 ), no MUC 1 
expression was detected in normal oral epithelium using DF3 as the anti-MUC 1 
monoclonal antibody. DF3 is against to an epitope in the DTRPAGS region of the 
MUC1 TR (Kufe et al., 1984). Sagara et al (1999) obtained similar results by 
showing that the DF3 epitope was not expressed in normal squamous epithelium 
of the esophagus. However, another MUC1 monoclonal antibody, BCP8, did 
150 
react with proteins expressed on membranes of normal cells. BCP8 is directed 
against MUC1 core peptide sequence PDTRPA in the TR (Agrawal et al., 1998d). 
Proteins reacting with both the DF3 and BCP8 antibodies were expressed in 
esophageal squamous-cell carcinomas . Cao et al (1997) reported that 
incomplete glycosylation, abnormal distribution, and ectopic expression of 
mucins are characteristics of malignancy . Lesions of higher grade dysplasia 
express MUC 1 with a lower degree of normal glycosylation or a remarkable 
variation in the glycosylation pattern, resulting in either more exposed peptide 
epitopes or tumor specific exposed peptide epitopes that can be recognized by 
their cognate antibodies (Dabelsteen et al., 1992; Cao et al., 1997). This explains 
why some MUC 1 monoclonal antibodies such as DF3 do not recognize the 
"normal " MUC1 protein. The monoclonal antibody E29 used in our study has 
been shown to react with epithelial membrane antigen (MUC 1) in a variety of 
both normal and neoplastic epithelial cells (Cordell et al., 1985). Therefore, it is 
not surprising that this antibody reacted with normal oral epithelial cells as well as 
ductal epithelial cells in our IHC experiments. Thus, the results of MUC1 IHC 
studies performed with different antibodies are difficult to compare and caution in 
interpretation of negative results is warranted. 
Cells in the basal layer of the oral buccal epithelium are the least 
differentiated. They undergo mitotic activity to provide for cell renewal and are 
pushed toward the surface by later renewing cells in the basal layer. Ultimately, 
the cells slough off from the superficial layer. Using the E29 antibody, MUC 1 
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protein was found in the normal maturing cells of prickle and intermediate layers 
in buccal epithelium. Cells in the superficial layer have fewer organelles so that 
there is less newly synthesized protein. No MUC1 expression was detected in 
these cells. Those MUC1 protein species in superficial layers that have reached 
the cell membrane during maturation are exposed to the oral cavity. Here, MUC1 
could interact with oral microorganisms or other proteins. This could result in 
either blocking of MUC 1 epitopes or "shedding" of MUC 1 protein from the cell 
membrane. Since the E29 antibody used in our study recognizes an epitope in 
the extracellular TR domain of MUC 1, it is likely that shedding of MUC 1 protein 
occurred since we did not observe strong staining in the superficial layer of 
normal oral buccal epithelial cells. 
We also detected MUC1 expression in gingival tissue taken during 
periodontal surgery from an adult patient with severe periodontitis. In this 
keratinized epithelium, MUC1 expression was observed in all layers above the 
basal layer and staining got stronger from the bottom layer to the more superficial 
layers. The overall staining pattern remained the same as in normal buccal 
epithelium, including the polarity of membranous · staining. However, staining in 
all cell layers of the inflamed gingival tissues was much stronger than that seen 
in normal epithelial tissues. This is consistent with the results of a previous study 
from our laboratory demonstrating that pro-inflammatory mediators and oral 
pathogens can increase MUC1 mRNA expression in oral epithelial cells (Li et al., 
2003a). 
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In conclusion, we have obtained evidence that normal human oral 
epithelia express both MUC1 mRNA and protein . Interestingly, protein 
expression is increased in inflamed gingival epithelial tissues . We hypothesize 
that MUC1 may constitute the base of a protective scaffold formed with other 
mucins and non-mucin proteins . This scaffold could protect epithelial cells in the 
oral cavity from chemical, mechanical, and bacterial injury. Therefore, the 
increased MUC 1 expression seen in inflamed gingival tissue may represent a 
novel host defense mechanism. 
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Part 2. Protein-protein interaction between MUC1 and MUC5B 
MUC5B is the major gel forming mucin secreted by human 
submandibular, sublingual and minor salivary glands. During the secretory 
process, MUC5B monomers form dimers through a series of disulfide bonds 
located in a Cystine Knot (CK) in the extreme C-terminal region of the apoprotein 
(Siqueira, 2003). By analogy to other gel-forming mucins, MUC5B dimers then 
form multimers through disulfide bonds located in the N-terminal cysteine-rich D 
domains (Perez-Vilar et al., 1998). 
MUC5B has the potential to interact with other proteins through protein 
domains, carbohydrate domains, or both. Because numerous ligand binding 
domains have been identified in the sequence of MUC5B, MUC5B may form 
heterotypic complexes with other proteins through its protein backbone 
(lontcheva et al., 1997). lontcheva et al (1997) showed that MUC5B forms 
complexes with amylase, praline-rich protein , statherin and histatin and have 
localized the sites of these interactions to non- or sparsely glycosylated cysteine-
rich protein domains in the TR and C-terminal regions of MUC5B (lontcheva et 
al., 2000). On the other hand, the gastrointestinal pathogen H. pylori (Veerman et 
a/., 1997) and the oral bacteria S. mutans (Gibbons and Qureshi, 1978) can bind 
to the glycans of MUC5B, while the polypeptide moiety of MUC5B is involved in 
binding H. influenza (Veerman et al., 1995). 
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MUC 1 is estimated to be 200 to 500 nm long and protrudes above the 
plasma membrane (Wesseling et al., 1995). Lillehoj et al (2001) reported that 
hamster Muc1 mucin on the epithelial cell surface is an adhesion site for P. 
aeruginosa and identified bacterial flagellin as the adhesion factor which is 
responsible for its binding to Muc1 mucin (Lillehoj et al., 2001; Lillehoj et al., 
2002). Other studies reported that TR domain of MUC1 mucin core protein binds 
to domain 1 of ICAM-1 (Hayashi et al., 2001 ). 
In the oral cavity, the membrane bound mucin MUC1 has been detected 
not only in the major and minor salivary glands but also in oral epithelial cells. 
Soluble MUC 1, presumably derived by shedding, has also been identified in 
salivary secretions (Liu et al., 2002a) . As noted above, we hypothesize that 
MUC 1 is involved in a protective layer on the surface of oral epithelial cells, upon 
which other salivary proteins including the gel-forming mucin MUC58 may bind. 
This seemed like a reasonable assumption since both MUC58 and MUC 1 have 
been shown to selectively bind other proteins. 
In this study, we set out to determine the composition of the MUC1 
protective layer. Our first set of experiments demonstrated that MUC 1 could, in 
fact, bind MUC5B. These interactions were shown to occur between the N-
terminal region of MUC 1 and the CK domain of MUC58. The N-terminal region of 
MUC 1 is the region that extends the farthest from the cell membrane, where it 
could likely interact with other proteins and trap microorganisms. The CK domain 
occurs at the extreme C-terminal region of MUC58. While other studies have 
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shown that this domain participates in MUC5B dimer formation, we have shown 
that it also is involved in binding to MUC 1. Further experiments are necessary to 
determine if MUC1 interacts with MUC5B monomers, dimers, or both. 
Interactions between MUC1 and MUC5B could maximize the protective functions 
of the secreted mucin MUC5B by prolonging its residence time in the oral cavity 
as well as to form the basis for protein scaffold which could protect the underlying 
epithelium from pathogenic microbes and other cytotoxic agents. 
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Part 3. MUC1 forms heterotypic protein complexes with other salivary 
proteins 
Our study showed that salivary mucin MUC5B could interact with the 
membrane bound mucin MUC1. In the oral cavity, there are other salivary mucins 
and numerous non-mucin salivary proteins as well as other cell surface proteins 
involved with cell adhesion, host immunity and other functions. 
It seemed likely that MUC1 might also interact with a subset of these 
proteins, imparting the mucin scaffold with diverse functional properties. In order 
to prove this hypothesis , we prepared two different MUC 1 constructs and used 
these constructs to screen a submandibular gland cDNA library in yeast two 
hybrid assays. 
The yeast two hybrid system, first described by Fields and Song in 1989 
(Fields and Song, 1989), is a novel genetic system to study protein-protein 
interactions by taking advantage of the properties of the GAL4 transcription factor 
in the yeast Saccharomyces cerevisiae. GAL4 is a transcriptional activator 
required for the expression of genes encoding enzymes of galactose utilization. It 
consists of two separable and functionally essential domains: an N-terminal 
GAL4 DNA binding domain (DNA-BO) and a C-terminal GAL4 activating domain 
(AD). Neither domain can activate transcription when expressed alone. Typically, 
the bait protein is fused to the DNA-BO, whereas the prey or a cDNA library is 
fused to the AD. When bait proteins interact with prey proteins in the yeast 
157 
nucleus, GAL4 will be reconstituted and the reporter genes, usually those 
encoding yeast nutrient growth markers, can be transcribed. 
In order to discover other MUC1 interacting proteins in the oral cavity, two 
MUC1 domains were fused with GAL4 DNA-BO, separately, in the yeast bait 
vector pGBKT7. These two domains are the N-terminal domain I of MUC1, which 
has been identified as the MUC5B binding domain, and the C-terminal domain II, 
which is the other less glycosylated extracellular region of MUC1 and occurs 
immediately following the TR domain. A submandibular gland cDNA library was 
fused with GAL4 AD in yeast prey vector pADT7-Rec. The bait and prey 
constructions were transformed into yeast strain Y187 and AH 109, respectively. 
When Y187 and AH109 were mated, interactions between MUC1 and proteins 
from the library reconstituted the functional transcription factor and the 
expression of the nutrient markers allowed the diploid cells to grow on the 
selective medium. DNA plasmids were extracted from the putative positive 
colonies, nucleotide sequences of inserts were determined and compared to 
those in GenBank using the BLAST program. 
Four proteins were identified as MUG 1 N-terminal domain I interacting 
proteins. Two of these were salivary proteins, the small secreted mucin, MUC7, 
and basic praline rich protein 3 (bPRP3). Two additional proteins were identified 
as M83 (TMEM8) and a protein similar to ICAM-3. Both of the latter proteins are 
membrane-associated proteins thought to be involved in the host immune 
response. 
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MUC7, the small secreted mucin in saliva, has been reported to bind other 
salivary proteins as well as oral microorganisms. MUC7 has been shown to 
interact with lactoferrin (Soares et al., 2003) and SlgA (Biesbrock et al., 1991) in 
salivary secretions. More recent studies have shown that the N-terminal domain 
of MUC7 also forms heterotypic complexes with amylase, PRP 3, histatins 1, 3, 
and 5 and statherin (Bruno, 2004). MUC7 is believed to play a key role in host 
defense in the oral cavity through its interactions with bacteria and yeast , 
resulting in microbial agglutination and aggregration (Slomiany et al., 1996). A 
MUC7 20-mer peptide (LAHQKPFIRKSYKCLHKRCR) possesses a broad-
spectrum antimicrobial activity (Bobek and Situ, 2003). A 12-mer cationic peptide 
(RKSYKCLHKRCR) within this region exhibits antifungal activity against C. 
albicans and Cryptococcus neoformans (Situ et al., 2003). 
Basic PRPs (bPRPs) are a family of at least 11 secretory salivary proteins. 
Kauffman (1991) described the relationships of ten bPRPs from a single 
individual: seven of them appeared to be formed from three larger precursors by 
selective posttranslational proteolysis of arginyl bonds; one of the basic proline-
rich proteins appeared to derive from human acidic praline-rich proteins; the 
remaining two were not consistent to any reported structures (Kauffman et al., 
1991 ). Basic praline-rich proteins form the largest group of proteins within human 
parotid saliva and some of them are O-glycosylated (Saitoh et al., 1983a; Saitoh 
et al., 1983b; Carpenter and Proctor, 1999). bPRPs are also found in 
submandibular/sublingual saliva (Robinson et al., 1989). Specific basic praline-
159 
rich proteins in human parotid saliva possess significant anti-HIV-I (Robinovitch 
et al., 2001) and C. albicans adhesion activity (O'Sullivan et al., 1997). They are 
multifunctional defense molecules in the oral cavity (Seeley, 2001 ). 
M83 (TMEM8) is a novel five-span transmembrane protein expressed on 
the cell surface as a glycosylated protein with molecular mass of 84 kDa 
(Motohashi et al., 2000). M83 mRNA is highly expressed in placenta, pancreas, 
and lymphohematopoietic tissues including peripheral blood, spleen, and bone 
marrow. Among hematopoietic cells, it is highly expressed in resting T 
lymphocytes and is downregulated by cell activation, particularly through T cell 
receptor/CD3 pathway. M83 is also down regulated during activation of B cells 
and monocytes. It indicates universal function of M83 in resting leukocytes. The 
C-terminal tail of M83 has two potential tyrosine phosphorylation sites, indicating 
its possible role in signal transduction cascade in response to its ligand or 
counter-receptor binding. 
ICAM-3 is a member of the immunoglobulin superfamily. It is a highly 
glycosylated protein of 124,000 daltons (de Fougerolles and Springer, 1992). 
Unlike ICAM-1 and ICAM-2, it is not expressed on endothelium but is expressed 
at high levels by resting leucocyte populations and antigen presenting cells. 
ICAM-3 is potentially the most important ligand for lymphocyte function-
associated molecule 1 (LFA-1) in the initiation of the immune response because 
of its expression pattern. It consists of five immunoglobulin domains, and binds 
LFA-1 through its first and second N-terminal lg-like C2-type domains (Fawcett et 
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al., 1992). MUC 1 is also expressed in lymphocytes and it fulfills the criteria for an 
early T-cell activation marker (Fattorossi et al., 2002). In this study, we found out 
that the fourth N-terminal lg-like C2-type domain could be a potential binding site 
for MUC1. Their interaction may modulate lymphocyte activation to adjust the 
host immune response. 
Four proteins were identified as MUC1 C-terminal domain II interacting 
proteins. Again, two of the proteins were known salivary proteins and two were 
not. Parotid secretory protein (PSP; residue 138-247) and basic PRPs were 
identified as salivary proteins interacting with MUC 1 and actin binding protein 280 
(filamin A, alpha, residue 1861-194 7) and epithelial cell receptor protein tyrosine 
kinase (EphA2, residue 311-410) were identified as cytoskeletal and cell 
signaling proteins interacting with MUC 1. 
Parotid secretory protein (PSP) has been detected in parotid gland, 
submandibular gland and saliva (Geetha et al., 2003; Mirels and Ball, 1992). It 
belongs to a family of oral and airway epithelial secretory proteins that are 
designated as PLUNC (palate, lung and nasal epithelium clone) proteins. These 
proteins are found in overlapping regions of the pulmonary, nasopharyngeal and 
oral epithelium. Members of the PLUNC family may function in the innate 
immune response in regions of the mouth, nose and lungs, which are sites of 
significant bacterial exposure (Bingle and Craven, 2002; Wheeler et al., 2002). 
Sequence-sequence comparison and sequence-structure analysis have 
revealed that PSP/PLUNC proteins are related to a family of mammalian lipid-
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binding proteins that includes bactericidal/permeability-increasing protein (BPI), 
lipopolysaccharide-binding protein (LBP), cholesteryl ester transport protein and 
phospholipid transport protein (Mulero et al., 2002). Geetha pointed out that 
PSP is similar to the endotoxin-binding proteins BPI and LBP and exhibits both 
anti-bacterial and anti-inflammatory activities (Geetha et al., 2003). The 
interaction between MUC1 and PSP may therefore serve important protective 
functions in the oral cavity. 
Actin-binding protein 280 (endothelial ABP-280, nonmuscle filamin) or 
· filamin A, alpha, is a 280 kDa ubiquitous dimeric actin cross-linking 
phosphoprotein of the peripheral cytoplasm, where it crosslinks actin filaments 
into orthogonal networks in the cortical cytoplasm and links actin filaments to 
membrane glycoproteins (Gori in et al., 1990). Fi lam in has 3 functional domains: 
an N-terminal filamentous actin-binding domain, a C-terminal self-association 
domain, and a membrane glycoprotein-binding domain. Filamins also bind over 
20 diverse cellular proteins, including membrane receptors and intracellular 
signalling macromolecules (Stossel et al., 2001). Filamin A can interact with Rho 
family GTPases (Ohta et al., 1999) and the serine/threonine kinase p21-activated 
kinase 1 (Vadlamudi et al., 2002). It also interacts constitutively with the insulin 
receptor to exert an inhibitory tone along the MAPK activation pathway (He et al., 
2003) . 
EphA2 is a member of the largest group of transmembrane receptor 
tyrosine kinase (RTKs) Eph receptors. It is a type I transmembrane protein. Both 
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the Eph receptors and their ephrin ligands are important mediators of cell-cell 
communication regulating cell attachment, shape, and mobility. Both Ephs and 
ephrins are membrane-bound and they are unique in that they mediate bi-
directional signaling, where information is transduced in both the receptor- and 
the ligand-expressing cells (Himanen and Nikolov, 2003). The EphA2 receptor 
tyrosine kinase is overexpressed in a variety of human cancers (Zeng et al., 
2003; Duxbury et al., 2004; Fox and Kandpal, 2004; Kataoka et al., 2004). It is 
both a determinant of malignant cellular behavior and a potential target for anti-
cancer therapies (Alves et al., 2003; Dobrzanski et al., 2004). EphA2 is also 
found on Langerhans like dendritic cells, inducing signaling as tyrosine 
phosphorylation and dephosphorylation of distinct proteins in the cells (Munthe et 
al., 2004). EphA2 is an essential regulator of post-natal angiogenesis because it 
regulates endothelial cell assembly and migration through phosphoinositide (Pl) 
3-kinase-mediated activation of Rac1 GTPase (Brantley-Sieders et al., 2004). 
EphA2 influences the regulation of its own gene expression. Specifically, ligand-
mediated phosphorylation of EphA2 transmits signals to the nucleus via 
extracellular signal-regulated kinase kinases to up-regulate de nova EphA2 gene 
expression and synthesis. This mechanism governs EphA2 expression in normal 
and malignant cells. In normal cells, EphA2 protein expression is balanced by 
ligand-mediated induction of EphA2 gene expression countered by EphA2 
protein turnover (Pratt and Kinch, 2003) . 
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In conclusion, oral epithelial cells express membrane bound mucin 
MUC1. The MUC1 protein on the epithelial surface can form complexes with 
other mucins such as MUC58 and MUC7; it can also interact with other salivary 
proteins such as basic PRP and parotid secretory protein. These protein-protein 
interactions may elongate the residence time and maximize the protective 
functions of salivary proteins in oral cavity. MUC1 also has potential binding 
ability with other transmembrane proteins. This is consistent with the known role 
of MUC 1 in cell signaling pathways. 
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